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ABSTRACT
The rise of Big Data has enabled sophisticated analysis of the human genome in unprece-
dented detail. Large datasets are now collected as a matter of routine, and their scope spans
multiple data types and multiple functional units at the molecular level of the cell. The breadth
and depth of these data offer the opportunity for complex experiments and extensive structural
modeling. But, given the intricacies of these data and the nuanced challenges they pose, robust
and rigorous methods are essential to ensure the value and validity of the resulting scientific
research. In this dissertation, we consider statistical methods for networks, applied to signaling
pathways in the human genome. We construct joint, integrative models that employ a variety
of data types simultaneously. These pathway models provide a unified approach to analysis of
genetic, epigenetic, transcriptomic, and other types of genomic data, and incorporate function-
ally meaningful biological relationships. In particular, we propose a new pathway model that
integrates non-coding micro RNAs, proteins that play a regulatory role with respect to genes.
We also propose methods to address obstacles that arise in the course of real-world research.
We consider missing data, a fundamental reality of -omics Big Data due to variability in data
quality and experimental design. We adapt a low-rank method for matrix completion to apply
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to bioinformatic datasets with arbitrary patterns of missing data. We apply the imputation and
pathway methods to a large-scale research study that profiles more than 30 cancer types. We
also propose an algorithm to identify important subnetworks within large signaling pathways,
in order to hone our understanding of the drivers of complex diseases. Through the use
of interactive data visualization and analysis, we promote access to -omics analyses. Taken
together, these methods provide a suite of tools that empower biological research using -omics
data. Our methods span functional genomic models, address real-world problems in data
analysis, and seek to make analysis of complex datasets more tractable, all while maintaining
a statistically sound foundation.
Linear Methods for Joint Analysis of Multivariate
Genomics Data
Matthew Henry Linder, B.A., M.S.
A Dissertation
Submitted in Partial Fulfillment of the
Requirements for the Degree of
Doctor of Philosophy
at the
University of Connecticut
2019
iCopyright by
Matthew Henry Linder
2019
ii
APPROVAL PAGE
Doctor of Philosophy Dissertation
Linear Methods for Joint Analysis of Multivariate Genomics
Data
Presented by
Matthew Henry Linder, B.A., M.S.
Major Advisor
Yuping Zhang
Associate Advisor
Ming-Hui Chen
Associate Advisor
Zhiyi Chi
Associate Advisor
Lynn Kuo
University of Connecticut
2019
iii
Dedication
To my mother Deborah, who taught me to love learning.
To my father Brett, who showed me how to think, inside and outside of the box.
To my brother Andrew, my role model for adventure and exploration.
To my partner Jaya, my endless companion in curiosity, fascination, and delight.
iv
Acknowledgements
I thank the Department of Statistics for the financial and intellectual support necessary to
earn this Ph.D. I would also like to thank Utility Operations & Energy Management at the
University’s Facilities Operations for ample opportunities to apply the statistics I learned to
real-world problems.
Thank you to Jaya Wen for her never-ending emotional, intellectual, and logistical support.
Without her, I might not have begun a Ph.D., and certainly would not have finished it.
Thank you to Nitis Mukhopadhyay for the passion with which he taught me mathematical
statistics; his humor; and the joy he brings to the classroom and those he teaches.
Thank you to Haim Bar for instruction in applied statistics, as well as consulting—in
particular, for introducing me to R Shiny, and cheering me on along the way.
Thank you to Jun Yan for nurturing my interest in computing, and permitting me the
freedom to learn on the job.
Thank you to Nalini Ravishanker for her generosity with her time and willingness to col-
laborate with me. In particular, I am grateful for her masterful intuition for organization and
logistics, and her encouragement that I dream big.
Thank you to Ming-Hui Chen for mentorship and friendship. So much of my experience
of graduate school was enriched and enlivened by his instruction, influence, and inspiration. I
cannot imagine this journey without him as a guide, role model, and companion.
Finally, thank you to my advisor Yuping Zhang, a source of enthusiasm, ambition, and
vsupport. Without her instruction and supervision, I could never have accomplished this thesis.
vi
Contents
Dedication iii
Acknowledgements iv
1 Introduction 1
1.1 Overview . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.1.1 Literature . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Overview of Datasets . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.1 The Cancer Genome Atlas . . . . . . . . . . . . . . . . . . . . . . . . . . 5
1.2.2 Pathway Interaction Database . . . . . . . . . . . . . . . . . . . . . . . 10
1.3 Dissertation Outline . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
2 Network models for integrative pathway analysis 13
2.1 Pathway analysis for -omics observations of gene activity . . . . . . . . . . . . . 15
2.2 miRNA-gene targeting . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
2.2.1 miRNA-gene target dataset . . . . . . . . . . . . . . . . . . . . . . . . . 22
2.2.2 Data processing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
2.2.3 Method . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
2.2.4 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
2.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 47
vii
3 Low-rank imputation of -omics missing data 49
3.0.1 Structured matrix completion . . . . . . . . . . . . . . . . . . . . . . . . 52
3.1 Integrated iterative imputation . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.2.1 Simulations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
3.2.2 EMC-NetGSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 64
3.2.3 miRNA-EMC-NetGSA analysis of breast tumor subtypes . . . . . . . . 81
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
4 Interactive data visualization and analysis 91
4.1 Interactive visualization for pre-defined pathways . . . . . . . . . . . . . . . . . 92
4.2 Interactive pathway analysis for subpathway identification . . . . . . . . . . . . 97
4.2.1 Greedy algorithm . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 99
4.2.2 Algorithm performance . . . . . . . . . . . . . . . . . . . . . . . . . . . 102
4.2.3 Analysis: results and visualization . . . . . . . . . . . . . . . . . . . . . 105
4.2.4 Interactive analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 111
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 113
5 Concluding Remarks and Future Research 116
5.1 Concluding Remarks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 116
5.2 Future Research . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
Bibliography 125
viii
List of Tables
1 Sample sizes for cancer and control populations in data for 32 cancers from The
Cancer Genome Atlas (TCGA). The cancer “code” is an abbreviation for each
cancer. All samples are from tissue in the afflicted, cancerous region. For the
cancer population, tissue samples are from tumorous tissue. For the normal
population, tissue is from healthy normal tissue. Cancers marked with a star
(?) were included in the analysis of pathway disturbance, on the basis of each
sample population including more than 10 samples. . . . . . . . . . . . . . . . . 8
2 In-degree by BRAF pathway gene, for edges into the gene from miRNAs. Values
count the number of edges into a given gene from any miRNA. . . . . . . . . . 41
3 TCGA cancer types used for BRAF signaling pathway data analysis. Given are
the TCGA cancer code abbreviation, cancer name, and sample population sizes
for tumor and normal tissue samples. Only TCGA cancers with gene expression
observations for all 10 BRAF pathway genes, as well as more than 10 samples
in each population, were considered. . . . . . . . . . . . . . . . . . . . . . . . . 42
4 Breast tumor subtype definitions and prevalence in data from The Cancer
Genome Atlas (TCGA). IHC status refers to immunohistochemical status for
the three specified genes. Prevalence measures a proportion. . . . . . . . . . . . 67
ix
5 Pairs of cancer and pathway for which the residual from a regression of the
logit(p)-value was negative, and larger in magnitude than a Bonferroni-adjusted
critical value. In sarcoma, we observe 8 disturbed pathways; in thymoma, we
observe 2 disturbed pathways; and we observe 1 pathway disturbance in each
of kidney renal clear cell carcinoma, ovarian serous cystadenocarcinoma, and
pancreatic adenocarcinoma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 79
6 Breast tumor molecular subtype sample sizes and prevalence in the TCGA
dataset. Also given are the overall sample size of all tumors and healthy breast
tissue. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
7 Subpathways which were consistent between the expression-only and integrated
analyses, and contained three or more genes. Cancers are labeled according to
the codes in Table 1 (BLCA is bladder urothelial carcinoma; BRCA is breast
invasive carcinoma; LUAD is lung adenocarcinoma; and THCA is thyroid car-
cinoma). p gives the total number of genes in the pathway, while q gives the
number of genes in the subpathway. . . . . . . . . . . . . . . . . . . . . . . . . 106
8 Subpathways that recurred exactly in multiple pathways for the same cancer,
under the EMC-NetGSA analysis. Cancer gives the cancer code from Table 1
(KIRP is kidney renal papillary cell carcinoma; LUAD is lung adenocarcinoma;
THCA is thyroid carcinoma). q is the number of genes in the subpathway, and
n is the number of pathways in which the subpathway recurred. . . . . . . . . . 108
xList of Figures
1 Sample sizes for TCGA populations with more than 10 samples. . . . . . . . . 8
2 A toy example of the integrated graph GmiEMC. White vertices (labeled “G”) are
gene expression nodes, which specify a signaling pathway topology. The three
miRNA nodes (red, labeled “mi”) target the genes, and methylation and copy
number nodes integrate the multi-platform, gene-level data (black and grey,
respectively). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 28
3 A simulated five-level binary tree signaling pathway. Shown is the treatment net-
work, which consists of: a full five-level binary tree of genes (large grey nodes);
miRNA targeting 1, 2, and 3 genes (colored red, yellow, and green, respectively);
and methylation and copy number nodes (white and black, respectively). Gene
“G01” corresponds to the root node, which is the first level of the binary tree;
“G02” and “G03” the second level; and so on. All integrated edges, that is,
those from miRNA, methylation, or copy number nodes, are directed into the
relevant gene node. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
xi
4 Boxplots of − log10 p-values from simulation study. The left-hand panel shows
significance tests for four gene sets of interest, under the first mean scenario in
which no -omics features exhibit differential activation. The right-hand panel
shows the second mean scenario, in which the top two-thirds of the simulated
binary tree signaling pathway is differentially activated, but the final third is
equal in the control and treatment populations. miEMC-NetGSA is shown in
green, miE-NetGSA in yellow, EMC-NetGSA in blue, and NetGSA (“E”) on
expression only in white. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 33
5 Network diagrams for the BRAF signaling pathway. The left-hand network is
the directed graph representing the BRAF genetic signaling pathway, consisting
of 10 genes with 12 directed edges between. The right-hand network contains
the same 10 gene vertices, but edges represent a shared miRNA parent. In
other words, two genes that share an edge are both targets of a single miRNA,
and possibly several. The graph contains 25 such edges. miRNA-gene targets
are chosen as those entries in the mirDIP database with with an “very high”
confidence score. Neither the BRAF nor MAP2K2 genes are targeted by any
miRNAs. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 36
xii
6 miRNA-gene interaction scores for all miRNA in TCGA dataset that target any
of the 10 genes that comprise the BRAF pathway. Scores are grouped by gene,
and colored by confidence class: very high, high, medium, and low confidence
are colored blue, green, yellow, and red, respectively. For our data analysis, we
included only miRNA-gene target interactions with “very high” confidence that
the interaction exists, i.e., the blue scores. . . . . . . . . . . . . . . . . . . . . . 38
7 Topology of subnetwork of the integrated BRAF signaling pathway correspond-
ing to the unweighted adjacency matrix A?mi in Equation 2.9, namely, the graph
formed by miRNA-gene targets. All edges are directed from the miRNA ver-
tex to the gene vertex. The miRNA node colors, edge widths, and edge colors
correspond to the degree of the miRNA vertex, that is, the number of genes in
the BRAF pathway targeted by a given miRNA. Grey graph nodes are genes,
while colored graph nodes are miRNAs, targeting 1 gene (red), 2 genes (yel-
low), 3 genes (green), 4 genes (blue), and 5 genes (purple). The genes BRAF
and MAP2K2 are not targeted by any genes. Darker edge colors correspond to
higher out-degree of the associated miRNA. . . . . . . . . . . . . . . . . . . . . 40
xiii
8 Results of significance tests for pathway disturbance in the BRAF pathway,
across 17 TCGA cancers. Barplots give values of− log10 p-values, after Benjamini-
Hochberg adjustment for multiple comparisons. Full gene expression miRNA
expression, and gene-level methylation and copy number is shown in green
(“miEMC”); integration of gene and miRNA expression is in yellow (“miE”);
integration of gene expression and gene-level methylation and copy number is
in blue (“EMC”); and the original, expression-only NetGSA results are in white
(“E”). The horizontal dotted line gives the significance threshold at the α = 0.05
level. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 44
9 Test statistics for pathway disturbance in 17 TCGA cancers, for the BRAF
pathway. Barplot heights give the test statistic value. miEMC-NetGSA is in
green, miE-NetGSA in yellow, EMC-NetGSA in blue, and NetGSA (“E”) in white. 45
10 Iterative integrated imputation with a toy example. X is a data matrix of 5
observation vectors with missing values that do not form a rectangle. Iteratively
for each column with missing elements xi (i = 3, 4, 5), we apply structured
matrix completion to the matrix χi, consisting of all complete data vectors; xi;
and any columns with missing values that are a subset of those missing from
xi. Imputation is performed on the entire rectangular submatrix of all features
missing in xi, with any observed elements not from xi treated as missing. So,
imputing x3 and x4 uses x5, whereas x5 is imputed using only the complete
data vectors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
xiv
11 Boxplots of − log10(p)-values for simulation study tests of pathway disturbance.
Network structure is a binary tree. X (shown in blue) represents EMC-NetGSA
applied to the complete data matrix, with no missing values. X˜ is the matrix
with all samples with any missing values dropped. I3 (in green) refers to our
integrated, iteratively imputed matrix. SMC uses imputed values obtained by
treating the entire minimal covering submatrix as missing, and KNN is K = 10-
nearest neighbors imputation. Horizontal line gives − log10(0.05). Scenario 1
(left): No features differential. Scenario 2 (right): Top 2/3 features differential. 61
12 Simulation results for missing data in a rectangular submatrix, using the sec-
ond mean scenario in which the top 2/3 of binary tree nodes are differentially
expressed. In this special case, our iterative imputation method (I3, in green)
has identical power to that of the basic SMC method. . . . . . . . . . . . . . . 63
13 − log10(p)-values for integrative tests of network disturbance in genetic signaling
pathways. Shown are pathways that changed significance after imputation in
at least one sample population. Separate differential analyses were performed
for each of four breast cancer subtypes, as well as a composite population of all
tumors. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
14 − log10(p)-values for significance tests of integrated genomics data for the entire
Smad2 / Smad3 signaling pathway and selected genes, by subtype. Gene-level
significance tests considered integrated triplets of pathway nodes, namely, ex-
pression, copy number, and methylation observations for each gene. . . . . . . . 70
xv
15 Coefficient estimates for expression in the Smad2 / Smad3 signaling pathway,
by subtype. Selected genes shown only. Coefficients were estimated separately
by population (cancerous tumor and healthy control). Within the tumor popu-
lation, separate estimates were obtained using the raw data with missing data
removed, and using the imputed data. . . . . . . . . . . . . . . . . . . . . . . . 71
16 Expression coefficient estimates for a selected subset of Smad2 / Smad3 sig-
naling pathway genes, by subtype. Coefficients were estimated separately by
population (cancerous tumor and healthy control). Within the tumor popula-
tion, separate estimates were obtained using the raw data with missing data
removed, and using the imputed data. . . . . . . . . . . . . . . . . . . . . . . . 73
17 Shown is the − log10(p) transformation of the BH-adjusted p-values obtained for
22 TCGA cancer types among 173 NCI PID pathways. Darker colors indicate
stronger significance, in terms of a smaller p-value. A white value indicates the
pathway was not tested for that cancer. We observe strong patterns of increased
significance across all pathways within individual cancers, such as elevated sig-
nificance in sarcoma (SARC) and thymoma (THYM) and reduced significance
in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ). We
also observe patterns in significance within pathways, across cancers, such as
elevated differential activity in B-cell receptor (BCR) signaling, and a lack of
disturbance in the glypican 2 and 3 networks. . . . . . . . . . . . . . . . . . . . 76
xvi
18 − log10(p)-values for the EPHA forward signaling pathway. Axis labels indicate
the integration scheme: miEMC is miRNA-EMC-NetGSA; miE is miRNA and
expression only; EMC is EMC-NetGSA; and E is NetGSA on gene expression
only. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 84
19 Network-adjusted expression parameters for EPHA4 in healthy tissue and tumor
subtypes. Integration of miRNA data only substantially alters the parameter
estimates for all subtypes, in terms of both magnitude and sign. But, joint
integration of miRNA, methylation, and copy number data clarifies and high-
lights the difference between the ER- HER2 over-expressed subtype and the
ER+ luminal subtypes, as well as the basal subtype. . . . . . . . . . . . . . . . 85
20 − log10(p)-values for the BCR pathway. Integration of miRNA data alone cap-
tures only marginal significance in the basal subtype. But, integration of miRNA
in conjunction with gene methylation and copy number boosts the signal in basal
subtypes, as well as the others, compared with integration of methylation and
copy number without miRNAs. . . . . . . . . . . . . . . . . . . . . . . . . . . . 86
21 HIF-2α transcription factor network . . . . . . . . . . . . . . . . . . . . . . . . 87
xvii
22 − log10(p)-values (top) and signed test statistics (bottom) for the signaling
events mediated by focal adhesion kinase pathway, in sarcoma cancer tumors.
These plots were generated procedurally using an interactive data visualiza-
tion application, publicly accessible online. Shown are the results of hypothesis
tests for the full pathway, as well as the -omics features for each individual
gene, tested as separate subpathways. The pathway analysis was performed on
a fully-integrated dataset consisting of expression, methylation, and copy num-
ber, using the EMC-NetGSA model; expression and methylation (EM-NetGSA);
expression and copy number (EC-NetGSA); and expression alone (NetGSA). . 95
23 Interface components for interactive data visualizations. Top left: Pathway
graph topology visualization, EMC-NetGSA analysis of breast cancer subtypes.
Top right: Inference outputs: p-values and test statistics, EMC-NetGSA pan-
cancer analysis. Bottom left: Coefficient estimates, miRNA-EMC-NetGSA anal-
ysis of breast cancer subtypes. Bottom right: Coefficient estimates, miRNA-
EMC-NetGSA pan-cancer analysis. . . . . . . . . . . . . . . . . . . . . . . . . . 97
24 Pathway for “signaling events mediated by PRL.” The subpathway genes are
shown in yellow (seed node) and orange. This subpathway of three genes was
obtained from bladder urothelial carcinoma (BLCA), and was identified consis-
tently in the NetGSA and EMC-NetGSA analyses. . . . . . . . . . . . . . . . . 107
xviii
25 Results of greedy algorithm for subpathway discovery, using NetGSA with ex-
pression values only (top), and integrated EMC-NetGSA (bottom). The sub-
pathway search was initialized using the single most significantly-disturbed gene
in the pathway. The subpathway was expanded by including adjacent genes that
increased the subpathway’s significance. Counts of gene occurrence in subpath-
ways for any signaling pathway, organized by cancer. Only genes that recurred
in some cancer across four or more pathways are shown. Genes identified in this
manner as “drivers” were broadly consistent in the two analyses. This suggests
these driver genes contribute to subpathway activity in a robust manner, and
are not merely spuriously significant genes. Integration of methylation and copy
number resulted in a larger number of driver genes within each cancer. More-
over, these significant driver genes do not recur in the same patterns across
multiple cancers, which indicates differential functions for these genes across
different cancers. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
1Chapter 1
Introduction
1.1 Overview
Systematic -omics research studies offer opportunities for comprehensive modeling of the hu-
man genome at the molecular level. These studies produce rich datasets measured across
hundreds of patients, providing not only biological insight into the healthy interoperation and
function of the cell, but also the opportunity to compare and contrast healthy and diseased
cells. Equipped with an improved understanding of the mechanisms that give genesis to com-
plex diseases, researchers will be more targeted in the development of treatments based on
specific molecular characteristics of disease, and clinicians will be better able to apply individ-
ualized treatments.
Integrated datasets observed on -omics data types beyond gene expression allow for an
unprecedented level of detail. The diversity of data available for study improves the detail with
which to characterize functional processes that underlie the genome. Multi-view datasets are
now routinely collected in multiple modalities across separate biological structures, and large-
scale research studies are coordinated to increase the quality and quantity of data available to
advance knowledge, treatment, and prevention.
Especially because of the complexity of data collection, processing, and multi-step analyses,
2it is critical to apply methods that are scientifically valid and statistically rigorous. Different
data types can provide new insight into unique facets of genomic systems, and deepen un-
derstanding of complicated biological functions. However, development of flexible statistical
methods for these trends in research and next-generation data platforms has not kept pace
with the speed of data collection. Moreover, the viability and validity of a statistical method
does not equate with accessibility and interpretability. Expressive tools for functional analysis
are critical to advance scientific understanding of the systems processes of the cell, and to
develop and utilize novel treatments for complex diseases with distinctive genomic characteris-
tics. Robust methods are essential to ensure scientific rigor and validity, and new experimental
techniques require novel analytic tools grounded in solid statistical theory.
This thesis contributes to active research in integrative genomics and the study of complex
disease by focusing on developing applied methods for biological analysis. Broadly, we consider
pathway analysis of functional gene networks, and implement several analyses on multiple
cancer types. In this introductory chapter, we provide an overview of literature related to
integration of multi-platform data collected at the level of the gene, in particular integration
of gene expression, methylation, and DNA copy number. We also review methods for pathway
analysis. We then introduce the primary datasets used in our analyses, specifically a large-scale
-omics dataset, and a source for known functional gene networks.
In Chapter 2, we discuss a model framework for pathway analysis of gene expression. We
also discuss an integrative extension of that model that incorporates additional -omics data
types collected at the level of genes. From these gene-level analyses, we progress to a novel
pathway model by further integrating non-gene functional units, embedded within the same
3pathway framework. Finally, we apply the fully-integrative analysis to an example signaling
pathway across multiple cancer types.
In Chapter 3, we consider missing data that often afflicts even the most comprehensive
-omics studies. A critical aspect of the analysis of genetic systems processes in a variety of
different cancer types is the availability of complete data for analysis. To remedy missing
data in -omics datasets, we consider an existing imputation procedure based on an assumption
that large-scale -omics data matrices exhibit low rank. We highlight the shortcomings of the
simple assumptions of that method. We propose a more comprehensive approach to accomplish
imputation of missing data in arbitrary configurations. We then perform pathway analysis of
breast tumor subtypes using the imputed dataset.
In Chapter 4, we discuss the use of interactive data visualization for exploration of the out-
put of pathway analysis for -omics Big Data. We provide an overview of a basic web application
that we use for exploratory data visualization of pathway outputs from the integrative models
discussed in Chapter 2 and implemented using imputed data from Chapter 3. We discuss four
implementations of the web application, for displaying pathway models with gene-level and
miRNA-gene integration, applied to multi-cancer datasets as well as breast tumor subtypes.
After reviewing the use of web applications for interactive data visualization, we discuss a
computational approach to identify subpathways of interest within larger signaling pathway
networks. We apply the approach to several datasets, and discuss the use of interactive tools
for interactive analysis.
Finally, Chapter 5 provides commentary on and discussion of the preceding chapters. We
also discuss avenues for further work in integrative pathway analysis.
41.1.1 Literature
To match the complexity and novelty of -omics datasets, statistical methods have been devel-
oped to model complex biological processes and to integrate multiple data types. The variety
of approaches available for analysis of -omics data is rich, and may address different dimensions
of genomic Big Data. Recent work has gone beyond simpler methods for statistical analysis,
such as gene-set enrichment analysis (GSEA; Subramanian et al., 2005), to emphasize appli-
cation of system-level models of biological processes. With respect to -omics datasets, basic
approaches often focus on a single data type. Gene expression and clinical covariates have been
applied to assess cancer survival outcomes across many different cancer types [Chandrashekar
et al., 2017], which leveraged the large sample sizes that are be available.
Systematic statistical models provide a solid theoretical foundation for integrative analysis.
Much work has been done to identify common signals across genomic features and -omics data
types. The iCluster model of Shen et al. [2009] applies PCA-style dimension reduction for
cluster analysis. PARADIGM [Vaske et al., 2010] uses network information to integrate -
omics data via a latent factor model. DIG [Zhang et al., 2017b] is a statistical framework for
estimating networks integrating multiple -omics data types and biological conditions. In their
clinical study, Danielsen et al. [2015] integrated the results of multiple separate analyses by
data type in an ad-hoc, manual fashion. This approach is typical of the literature.
Integrative analyses offer unified approach for joint analysis of a large number of genomic
features across multiple data platforms. Linear methods have been applied to gene-level mea-
surements of expression, methylation, and copy number within individual cancers [Network
et al., 2017], emphasizing the aggregate information obtained from distinct data platforms. In
5addition to using integration to increase knowledge of molecular processes, integrative analysis
has also been applied with a focus on clinical survival outcomes across multiple cancers [Liu
et al., 2018].
Pathway analysis offers a more systematic, structural approach to modeling genomic pro-
cesses [Yan et al., 2017]. Pathway analysis incorporates knowledge of biological network struc-
ture into statistical models of expression. Pathway models such as the NetGSA model [Shojaie
and Michailidis, 2009] (discussed in detail below) exploit results from graph theory to account
for co-expression due to pass-through effects from features with differential activity to those
that are not.
1.2 Overview of Datasets
1.2.1 The Cancer Genome Atlas
The Cancer Genome Atlas (TCGA) [Tomczak et al., 2015] is a long-running international study,
funded by the National Cancer Institute (NCI), to collect observations of cancerous tissue in
more than 30 cancers and across multiple distinct -omics data platforms. We downloaded the
TCGA data from the NCI Genomic Data Commons (GDC; Grossman et al., 2016), using the
TCGA-Assembler software, v2.0.0 [Zhu et al., 2014, Wei et al., 2017].
We obtained level-3 TCGA data for 33 cancers. The data were collected from individ-
ual subjects, and we obtained subject-level covariates that included sex, survival outcomes,
and other phenotypic information. Within a single subject, multiple tissue samples may be
obtained. For a given cancer, the tissue was collected from the anatomical region that corre-
sponds with the cancer type. For example, breast cancer data was collected from breast tissue.
6Tissue samples were classified at the time of collection as belonging to one of more than one
dozen tissue types. The population sample sizes are given in Table 1. The samples sizes for
populations with at least 10 samples are shown in Figure 1. The data exhibit a systematic
imbalance between the two populations, with the number of tumor sample consistently higher
than the number of healthy samples.
Sample sizes
Cancer Code Cancer Normal
Adrenocortical carcinoma ACC 92 5
Bladder urothelial carcinoma? BLCA 412 36
Breast invasive carcinoma? BRCA 1096 161
Cervical squamous cell carcinoma and endocervical adenocarcinoma CESC 308 8
Cholangiocarcinoma? CHOL 36 15
Colon adenocarcinoma? COAD 455 92
Lymphoid neoplasm diffuse large B-cell lymphoma DLBC 48 0
Esophageal carcinoma? ESCA 185 64
Glioblastoma multiform? GBM 586 31
Head and neck squamous cell carcinoma? HNSC 528 82
Kidney chromophobe renal cell carcinoma? KICH 66 57
Kidney renal clear cell carcinoma? KIRC 534 427
Kidney renal papillary cell carcinoma? KIRP 291 87
Brain lower grade glioma LGG 516 0
Liver hepatocellular carcinoma? LIHC 377 87
7Lung adenocarcinoma? LUAD 519 179
Lung squamous cell carcinoma? LUSC 504 240
Mesothelioma MESO 87 1
Ovarian serous cystadenocarcinoma? OV 586 130
Pancreatic adenocarcinoma? PAAD 185 37
Pheochromocytoma and paraganglioma PCPG 179 5
Prostate adenocarcinoma? PRAD 500 117
Rectum adenocarcinoma? READ 167 17
Sarcoma? SARC 261 22
Skin cutaneous melanoma SKCM 104 3
Stomach adenocarcinoma? STAD 478 131
Testicular germ cell tumors TGCT 150 0
Thyroid carcinoma? THCA 507 99
Thymoma? THYM 124 12
Uterine corpus endometrial carcinoma? UCEC 545 51
Uterine carcinosarcoma UCS 57 6
Uveal melanoma UVM 80 0
8BLCA BRCA CHOL COAD ESCA GBM HNSC KICH KIRC KIRP LIHC LUAD LUSC OV PAAD PRAD READ SARC STAD THCA THYM UCEC
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Figure 1: Sample sizes for TCGA populations with more than 10 samples.
Table 1: Sample sizes for cancer and control populations in
data for 32 cancers from The Cancer Genome Atlas (TCGA).
The cancer “code” is an abbreviation for each cancer. All
samples are from tissue in the afflicted, cancerous region. For
the cancer population, tissue samples are from tumorous tis-
sue. For the normal population, tissue is from healthy normal
tissue. Cancers marked with a star (?) were included in the
analysis of pathway disturbance, on the basis of each sample
population including more than 10 samples.
For our analysis, we downloaded and considered tissue collected from either “primary solid
tumor” or “solid normal” tissue. We constructed sample populations from these two tissue
types, so the populations permit comparison of tumorous and healthy tissue from the same
location. Because of their situation within the corresponding tissue, we refer to the non-tumor
9samples as matched normal tissue.
For each tumor and matched normal tissue sample, we obtained multi-platform -omics
data, collected on the following platforms.
1. Gene expression was measured on the Illumina HiSeq RNASeqV2 platform. Level-3
TCGA data was available as both raw read counts, and a normalized format. The latter
is provided as fragments per kilobase of transcript per million mapped reads (FPKM),
normalized as the upper quartile (UQ) of nonzero counts [Dillies et al., 2013, Grossman
et al., 2016], or FPKM-UQ. We used these normalized values rather than the raw read
counts.
2. DNA copy number variation (CNV) was collected using the Affymetrix Genome-Wide
Human SNP Array 6.0 platform. We used data with germline copy number variants
removed.
3. DNA methylation was measured using the HumanMethylation450 BeadChip. Observa-
tions are organized at the level of CpG sites.
We also obtained micro RNA (miRNA) observations that were collected on the Illumina
HiSeq platform. We defer details of miRNA data processing until Section 2.2 below.
We performed additional data processing after downloading from TCGA, prior to analysis.
1. We applied a log2 transformation to the RNASeq data.
2. We averaged gene-level CNV by DNA region.
3. We averaged gene-level methylation beta values across all CpG sites for each gene.
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1.2.2 Pathway Interaction Database
Much of the analysis that follows is oriented toward network analysis of genetic signaling
pathways. To this end, we downloaded the 212 signaling pathways that comprise the NCI
Pathway Interaction Database (PID, Schaefer et al., 2008). To obtain the PID, a collection
of known gene networks specified as directed, functional relationships between genes, we used
the graphite software [Sales et al., 2018] within R.
The PID pathways are defined over 2393 genes, which correspond to 2369 genes observed on
6973 -omics features in the TCGA dataset, across the three gene-level platforms for expression,
methylation, and copy number. In particular, within each data type, we observed 2363 genes
with expression measurements, 2279 genes with methylation, and 2331 genes with copy number.
Of the 212 pathways that comprise the PID, 173 pathways were such that observations of
expression were available for every gene in the pathway. The number of missing genes per
pathway was one gene for 32 pathways, two genes for four pathways, three genes for one
pathway, and four genes for two pathways.
1.3 Dissertation Outline
In this thesis, we considered several methods and procedures oriented towards integrative
pathway analysis. These methods not only offer statistical models for signaling pathways that
integrate multiple -omics data types, but also address real-world obstacles to applications,
including missing data, effective communication and exploration of statistical output, and a
computational method to identify important subpathways in known pathways.
In Chapter 1, we discussed the importance of -omics studies for understanding complex
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diseases. We discussed some contemporary research in integrative genomics. We introduced a
large-scale, ongoing research study, The Cancer Genome Atlas (TCGA), that provides access
to multi-platform genomic data on cancer. We also discussed a dataset of signaling pathways,
the NCI Pathway Interaction Database.
In Chapter 2, we gave an overview of approaches to pathway analysis of functional networks
of genes. We gave an overview of a basic pathway model, NetGSA, as well as EMC-NetGSA, an
integrative adaptation that jointly models gene expression, methylation, and copy number. We
then introduced non-coding micro RNAs (miRNAs), and discussed their role in gene regulation.
We introduced a dataset of functional miRNA-gene target relationships, and we proposed an
extension of EMC-NetGSA that also includes miRNAs. This approach provides a secondary
mechanism to account for correlation across genes beyond the graph topology of the signaling
pathway. We demonstrated the method on an example pathway, using the TCGA dataset.
In Chapter 3, we presented a procedure to impute missing data in integrative genomics. We
applied a matrix completion method in an iterative fashion, imputing non-rectangular missing
data in a way that uses all available information in a genomic sample. Our approach permits
application of a theoretically-appealing model for imputation to real-world data. We applied
pathway analysis to the imputed data, and demonstrated through simulation the increased
power of our strategy, with a smaller rise in false discoveries than the original SMC method.
We demonstrated that the I3 method improves the precision of the basic SMC method, while
still leveraging the linear dependencies that make SMC attractive in the first place.
Our data analysis demonstrated the power to stabilize coefficient estimates of subtypes,
despite small sample sizes. Furthermore, it reinforced the importance of subtype analysis of
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tumors, rather than across entire populations. Among the pathways in the NCI Pathway In-
teraction Database, we found many possible pathway disturbances. Some of these pathways
play known roles in breast cancer, which supports evidence of disturbance in other path-
ways not previously known. The FOXA2 and FOXA3 transcription factor networks and the
ErbB2/ErbB3 signaling events pathways, in particular, displayed pathway disturbances that
have been relatively unexplored in breast cancer. Based on the results of the simulation study
and the data analysis, iterative integrated imputation (I3) struck a balance between local ac-
curacy and global structural constraints when imputing missing data. We demonstrated the
bias introduced by the assumption that missing data occurs in blocks, and we propose a pro-
cedure based on SMC that includes the original block-missing SMC as a special case, while
flexibly handling non-rectangular missing data. Our method imputed values that permit anal-
ysis of datasets with missing data, without providing imputed values that distort the output
statistical analysis.
In Chapter 4, we discussed the challenges posed by large-scale data analysis of -omics Big
Data. We reviewed some existing approaches to interactive data visualization, and we provided
details of an interactive data visualization that gives access to our own pathway analysis of
the previous chapters. We also discussed subpathway discovery, for the purposes of identifying
important subnetworks among a broader pathway network. We proposed a greedy search
algorithm, and implemented the procedure on both expression-only and integrated datasets.
We also discussed the combinatoric and computational challenges posed by subgraph searches,
and gave details of an interactive analysis tool that permits user-specified subpathway analysis.
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Chapter 2
Network models for integrative
pathway analysis
In this chapter, we discuss pathway analysis for -omics data that comprise known signaling
pathways. These pathways are specified as known, directed graphs, with graph vertices that
represent -omics features, and directed graph edges that represent known functional relation-
ships.
Application of GSEA to genes a priori known to comprise a signaling pathway can give
comparative insight into patterns of differential activity across multiple cancers [Ge et al., 2018].
But, more mature pathway methods have been introduced and applied. The random walk with
restart has been applied to assess both network cohesion and compare the explanatory power of
several different pathway databases [Huang et al., 2018]. The SAFE model [Baryshnikova, 2016]
identifies local neighborhoods of high enrichment situated within larger networks. A factor
model approach, PARADIGM, was applied to a single unified network of multiple signaling
pathways [Vaske et al., 2010], and has also been used for comparative analysis of individual
pathways across cancer types [Campbell et al., 2018]. Graphical methods have also been
developed, for directed as well as undirected Gaussian networks [Ma et al., 2014b].
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In Section 2.1, we provide an overview an overview of the NetGSA framework for joint
modeling of gene expression observations that correspond to the vertices in a graph for a ge-
netic signaling pathway. The framework also offers hypothesis testing of differential expression
between two populations, which we situate within the context of cancer and healthy popula-
tions. We also discuss an integrative refinement of the NetGSA model, EMC-NetGSA, which
provides a joint model for several -omics data types observed at the gene level.
A natural fusion combines data integration and pathway analysis. This has been applied
to comprehensive analysis of individual signaling pathway in a single cancer using gene-level
covariates including expression, methylation, and copy number, and somatic mutations to
analyze androgen receptor signaling[Robinson et al., 2015]. Also available for integration in
pathway analysis is inclusion of non-gene features, like miRNA expression along with gene
expression, methylation, and DNA copy number [Danielsen et al., 2015]. Pathway analysis has
also been applied across multiple cancers and multiple pathways [Sanchez-Vega et al., 2018],
and the Lemon-Tree model [Bonnet et al., 2015] used a module network model to integrate
data and identify novel pathway components.
In Section 2.2, we propose a further extension of the EMC-NetGSA model to integrate
-omics data collected for biomolecular units other than the gene, namely, non-coding micro
RNAs. We implement and discuss a data analysis of the BRAF pathway to demonstrate the
new integrative method.
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2.1 Pathway analysis for -omics observations of gene activity
The NetGSA model, introduced by Shojaie and Michailidis [2009], offers a graphical model
for joint modeling of gene expression. The model accounts for known functional dependencies
between genes comprising a signaling pathway. As originally proposed, the model applied only
to directed acyclic graphs (DAGs). The same model was shown by Shojaie and Michailidis
[2010] to apply to a more general class of directed graphs. Moreover, that same work proposed
a procedure to apply the basic NetGSA model to arbitrary directed graphs. The work of Ma
et al. [2014b] extended the model further, to include undirected Gaussian networks.
Each of these iterations on the basic NetGSA framework focused on signaling pathway
graphs and models of gene expression. The model was further extended by Zhang et al. [2017a]
to the -omics setting. Their integrative EMC-NetGSA was so named because it provides a
joint model for expression, methylation, and copy number data, each observed at the level of
individual genes.
We proceed constructively. We start with a genetic signaling pathway specifying known
functional relationships between p genes. We represent the pathway as a directed graph G =
{V, E}, where V is a set of p graph vertices, and E is a set of directed edges between elements
of V. The graph vertices in V represent genes, while the edges in E represent the functional
pathway interactions.
We represent the graph topology of G by a p× p graph adjacency matrix, denoted A?E. We
use the subscript “E” to emphasize that the graph specifies relationships between vertices that
represent measurements of gene expression. The element αjk of A?E takes the value 1 if there
exists a directed edge from vertex k to vertex j, and 0 otherwise, for all j, k = 1, . . . , p. αjk
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may be interpreted as an indicator function for the conditional dependence of gene j on gene
k. Corresponding to each gene we observe gene expression, which we format as a vector with
p elements, yi1, where i = 1, . . . , N indexes each of N independent samples.
For each element in yi1, we also observe copy number and methylation beta values for
the corresponding genes. Denote the vectors of methylation and copy number by yi2 and
yi3, respectively. The EMC-NetGSA integration procedure, proposed in Zhang et al. [2017a],
incorporates the methylation and copy number measurements into the graph topology of G. In
particular, we augment G by adding 2p vertices to V, one each for methylation and copy number
for every gene. We also add 2p edges to E , directed from the methylation or copy number vertex
to the corresponding gene expression vertex. Therefore, the final EMC-NetGSA graph consists
of two separate layers of network topology:
1. The primary, inter-gene signaling pathway network, giving edges between elements of
yi1;
2. A secondary integration network of edges between elements of yi2 or yi3, and the corre-
sponding elements in yi1.
Denote the full observation vector for sample i by yi123 = (y′i1,y′i2,y′i3)′. For some genes,
copy number or methylation values are unavailable, and in these cases, the number of copy
number (methylation) observations in yi2 (yi3) will be less than p. We resolve this by removing
the non-expression vertex from V and the corresponding integrated edge from E . Without loss
of generality, we assume yi2 and yi3 each contain p elements, and adjust yi123 accordingly.
The EMC-NetGSA integration is implemented in the adjacency matrix by concatenating
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identity matrices along the right-hand margin and zero matrices along the bottom:
A?EMC =
A
?
E Ip×p Ip×p
O2p×p O2p×p O2p×p
 (2.1)
where O2p×p is a 2p× p matrix of zeros. Here, the identity matrices reflect the directed edges
from copy number and methylation vertices to expression, and the zero matrices reflect the lack
of any network structure within or between the additional data types, or a directed relationship
from genes to -omics features.
Each pair of vertices in {(j, k) | αjk 6= 0}, where αjk is an element of A?EMC, specifies a
directed edge from yik to yij , i = 1, . . . , N , yik, yij ∈ yi123. This is a conditional dependence
relation of vertex j on vertex k, given the effects of the other (3p− 2) network features. In the
context of Gaussian graphical models, conditional dependence of random variables Xj and Xk,
conditional on a set Z of additional random variables of interest, is formalized as the partial
correlation ρjk with respect to Z. That is, ρjk = corr(Xj\Z , Xk\Z), where Xj\Z = Xj −PZXj
is the orthogonal complement of Xj with respect to Z, and PZ is a projection onto Z [Krämer
et al., 2009]. Intuitively, ρjk represents the association between -omics features j and k,
controlling for each of their associations with other features in the pathway. We estimate
ρjk by the sample partial correlation rjk, which is obtained by regressing each of Xj and Xk
separately on Z, and then calculating Pearson’s correlation coefficient between the vectors
of residuals. Using the partial correlations and A?EMC, we construct the weighted adjacency
matrix AEMC with elements ajk = rjkαjk, j, k = 1, . . . , 3p.
To build a statistical model for the data {yi123}Ni=1, we consider a transformation of AEMC
18
introduced by Shojaie and Michailidis [2009]. The influence matrix ΛEMC captures the cumu-
lative network effect of each gene on the expression of all others. In the case of directed acyclic
graphs (DAGs), the authors derive the identity ΛEMC = (I3p −AEMC)−1.
Shojaie and Michailidis [2010] extended this formula to apply to general, non-DAG graphs.
In particular, they demonstrate that the relationship between the influence and adjacency
matrices applies to any graph that is substochastic, which occurs when the adjacency matrix
has eigenvalues all of which have magnitude smaller than 1. They apply a graph theoretic
result, Gershgorin’s Disk Theorem, to obtain a limit approximation for the influence matrix
when the adjacency matrix is not substochastic, in particular,
α(δ) = (αjk(δ))j=1,...,3p;k=1,...,3p, δ > 0 (2.2)
αjk(δ) =
AEMCjk
(∑3p`=1 |AEMCj`|) + δ (2.3)
ΛEMC = lim
δ→0
(I3p −α(δ))−1 (2.4)
Then, an approximation to ΛEMC is constructed using a small value of δ > 0.
The EMC-NetGSA model uses ΛEMC to structure the mean in a mixed-effects model with
unknown regression coefficients βEMC ∈ R3p, with Eyi123 = ΛEMCβEMC. We may interpret
βEMC as the network-adjusted expression coefficients for the 3p -omics features, and we note
ΛEMC also structures the covariance of yi123.
The NetGSA framework also provides for significance testing of two populations, control
(healthy) and treatment (disease). Denote the population label for sample i as ci ∈ {C,T}.
The control and treatment populations are modeled using separate adjacency matrices ACEMC,
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ATEMC, corresponding to influence matrices ΛCEMC, ΛTEMC, and parameterized with population-
specific pathway-adjusted expression parameters βCEMC,βTEMC, respectively.
The EMC-NetGSA statistical model is then given by
yi123 = ΛciEMCβ
ci
EMC + Λ
ci
EMCγi123 + i123, i = 1, . . . , N (2.5)
γi123 ∼ N3p(03p, σ2γI3p) (2.6)
i123 ∼ N3p(03p, σ2 I3p) (2.7)
To test differential activity in subsets of the pathway’s genomic features, represented by
elements of βCEMC and βTEMC, we specify features of interest through an indicator vector b.
We use the NetGSA network contrast `EMC = (−b · bΛCEMC,b · bΛTEMC) to compute the
test statistic TEMC ∝ `βEMC, where βEMC = (βC′EMC,βT
′
EMC)′. TEMC follows a Student’s t
distribution with degrees of freedom estimated by the Satterthwaite approximation.
2.2 miRNA-gene targeting
Bioinformatic data is increasingly collected from functional genomic units in the cell other
than genes. These new genomic entities present new opportunities for integrative analysis, and
include non-coding micro RNAs (miRNAs). These small, noncoding RNAs are understood to
play a regulatory role for genes, and the identification of miRNA-gene targets is critical to
understanding the biological function of each [Hammond, 2015].
However, to date, development of advanced statistical methods has lagged behind the rapid
growth in experimental methods and available data. We address the lack of sophisticated
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technical methods by proposing an integrated model for simultaneous network analysis of
miRNA-gene target interactions and their association with genetic signaling pathways. We
extend existing methods for graphical analysis of gene-level -omics data, specifically the EMC-
NetGSA model, to include functional relationships between miRNAs and genes. In particular,
we represent miRNA-gene target relationships through the same graphical structure as we used
in the previous section to integrate methylation and copy number.
Individual miRNA are believed to target genes in a functional manner [Lewis et al., 2005],
and it is often the case that single miRNAs target multiple genes. To model correlated gene
activity due to a shared miRNA parent, miRNA-gene target interactions must be known and
available to researchers. Early miRNA-gene target research validated individual targets exper-
imentally, but the combinatoric problems introduced by large numbers of genes and miRNAs
motivated meta-analytic and computational approaches. One study to identify miRNA-gene
targets was miRTarBase [Hsu et al., 2010], which identified gene targets for fewer than 700
miRNAs by manual aggregation of experimental evidence. Despite the intensive cost of this
type of study, the authors anticipated the use of small, manually-integrated datasets as inputs
to computational approaches to identify interactions.
Computational resources such as the miRTar [Hsu et al., 2011] and miRDIP [Tokar et al.,
2017] aggregate individual experimental findings on miRNA-gene target relationships. These
centralized databases offer a starting point for more sophisticated functional analysis across
datasets with thousands of genomic features, reducing the combinatoric burden of a purely
computational association analysis between miRNAs and genes.
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Early statistical analyses of miRNAs were characterized by straightforward statistical meth-
ods. For example, the CORNA method introduced by Wu and Watson [2009] applied methods
including the hypergeometric and Fisher’s exact tests to assess differential activity in miRNA-
gene interactions and networks. Subsequently, miRNA analysis has gained popularity in appli-
cation to cancer datasets. Enerly et al. [2011] studied miRNA suppression in a novel miRNA
and gene expression breast tumor dataset. They observed roles played by miRNAs in genetic
activity, immunohistochemical characteristics, and system-level cellular processes. Yu et al.
[2019] identified specific biomarkers with differential survival outcomes in lung cancer. Li et al.
[2018] used differential correlation analysis between miRNAs and genes in cancer and normal
populations, which they applied across multiple distinct cancer types.
Joint analysis of separate functional components may integrate marginally univariate data,
such as miRNA expression paired with gene expression [Chu et al., 2015]. But, multi-level
integrative analysis is also performed, such as an analysis of breast and gynecological cancers
including somatic mutations and copy number, gene expression, methylation, and multiple
types of non-coding RNA [Berger et al., 2018].
The nature of miRNA research is foundationally integrative in nature, given the funda-
mental nature of miRNA-gene interactions. Nevertheless, integrative analysis is not restricted
to focus on the relationship between miRNAs and genes. Some researchers integrate epige-
netic data, including Miao et al. [2017], who analyzed the relationship between miRNAs and
DNA methylation in sheep. Du and Zhang [2015] integrated methylation in a small-sample
analysis of lung cancer that also included expression in genes and miRNAs. Volinia and Croce
[2013] applied a similar approach to breast cancer data. Transcriptomic data has also been
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integrated: Cava et al. [2014] considered copy number as well as gene and miRNA expression.
Modern informatic methods permit large-scale analyses to identify miRNA targets. Frame-
works such as miRTarBase and DIANA-miRPath [Vlachos et al., 2015] utilize web interfaces to
access and explore association analyses between miRNAs and genes. DIANA-miRPath adapts
methods originally applied to gene expression. In addition to Fisher’s exact test, they also test
for differential activity in miRNAs using the enrichment analysis method of Bleazard et al.
[2015]. Computational approaches have been used to identify targets, too. Hsu et al. [2011]
proposed miRTar, a successor to miRTarBase that used gene set enrichment analysis for signifi-
cance testing of differential activity. These are often applied to specific phenomena or systems.
Other databases include DIANA-TarBase [Karagkouni et al., 2017] and TargetScan [Agarwal
et al., 2015]. Coll et al. [2015] used correlation analysis to find miRNA-gene targets related to
cirrhosis of liver tissue. Godard and van Eyll [2015] performed pathway analysis of miRNA in
the context of Alzheimer’s disease with an approach derived from enrichment analysis. But,
methods for comprehensive, graph-theoretic pathway analysis remain undeveloped.
2.2.1 miRNA-gene target dataset
As described above in Section 1.2.1, it is straightforward to construct a direct mapping be-
tween the basic methylation and copy number features, on the one hand, and a single gene,
on the other. In contrast, no such standard, direct mapping exists between genes and miR-
NAs. Instead, we use resources on functional miRNA-gene targets to construct an integrated
statistical model. Substantial work has been done to identify miRNA-gene targets. One re-
source that quantifies the degree of experimental evidence in support of a given miRNA-gene
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target interaction is mirDIP. Tokar et al. [2017] compiled the database as a meta-analysis to
integrate predicted miRNA-gene targets from 30 separate sources of experimentally-validated
interactions. It includes information on the degree to which the source databases overlap in
their conclusion.
2.2.2 Data processing
As discussed above in Section 1.2.1, we aggregated expression, methylation, and copy number
data at the level of individual genes. Similar to gene expression, miRNA expression data
are available from TCGA in two formats: raw read counts, and normalized reads-per-million
(RPM). Raw read counts were collected on the miRNASeq platform, and the TCGA processing
pipeline outlined by Chu et al. [2015] is consistent with procedures in comparable projects,
such as ENCODE [Consortium et al., 2012]. After alignment and read trimming, a library of
approximately 22 base pairs of mature strands was used with an insert length of approximately
22.
Typical miRNASeq analyses use methods traditionally developed for RNASeq. For ex-
ample, Stokowy et al. [2014] employed RPM normalization and cited its original definition
from Mortazavi et al. [2008], in the context of gene expression. They cited other work that
applies RPM normalization to miRNASeq data, including Chen et al. [2013]. Following RPM
normalization but prior to the primary analysis, those authors applied a log2 transformation.
Han et al. [2018] integrated gene and miRNA expression. They first applied FPKM-UQ nor-
malization RNASeq gene expression values, then calculated RPM for miRNASeq values and
transformed logarithmically. TCGA provides RPM normalized transformation of the data, so
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for our integrative analysis, we applied a log2 transformation to the RPM-normalized values.
Empirically, we observed that this normalization was comparable to FPKM-UQ applied to the
raw read counts.
2.2.3 Method
Integration of miRNA observations into the NetGSA framework proceeds from a known set
of functional miRNA-gene target relationships. In addition to the signaling pathway topology
represented in the adjacency matrix A?E, we also consider g miRNAs with known functional
targets among the p genes observed in yi1. For each sample, we observe a vector of g elements
yi4, i = 1, . . . , N , the values of which measure miRNA expression.
To represent the miRNA-gene target interactions, we construct a p×g graph adjacency ma-
trix A?mi, with columns that correspond to miRNAs and rows that correspond to genes. Then,
as before in the NetGSA and EMC-NetGSA models, the element τj` of A?mi is an indicator
value for miRNA ` targeting gene j, j = 1, . . . , p, ` = 1, . . . , g. Here, we have represented each
miRNA-gene target as a directed edge, and τj` = 1(Gene j is conditionally dependent on miRNA `).
We construct an integrated adjacency matrix A?miE that includes both the signaling pathway
and the miRNA-gene targets:
A?miE =
A
?
E A?mi
Og×p Og×g
 (2.8)
which is a square (p + g) × (p + g) matrix with elements taking values of either 0 or 1.
Correspondingly, we integrate the graph G by adding g vertices to V, one for each miRNA.
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For each miRNA-gene target, we add to E a directed edge from the miRNA vertex to the gene
vertex.
Then, we use the EMC-NetGSA method to construct a fully-integrated adjacency matrix,
by augmenting V to contain a total of (3p + g) vertices, and adding the corresponding 2p
additional edges from the methylation and copy number vertices to the corresponding gene
expression vertex.
Mechanically, this integration scheme produces another, fully-integrated adjacency matrix,
A?miEMC, which composes A?miE with identity matrices:
A?miEMC =
A
?
E Ip×p Ip×p A?mi
O(g+2p)×p O(g+2p)×p O(g+2p)×p O(g+2p)×g
 (2.9)
where Om×n is am×n matrix of zeros. The identity matrices reflect that the network topology
consists of (1) directed edges between elements of yi1, and (2) directed edges from elements in
yi2,yi3,yi4 to associated elements in yi1. In particular, we do not model any directed network
effect from genes to any of miRNAs, methylation, or copy number vertices. As before, without
loss of generality, we consider the full (g + 3p)× (g + 3p) adjacency matrix A?miEMC, with the
knowledge that its true dimension q is such that q ≤ (g + 3p).
We may interpret the network adjacency matrix specified in Equation 2.9 as a composition
of three distinct network layers: (1) a primary network specified between elements of yi1; (2)
a miRNA-gene integration layer giving directed network relationships, possibly many-to-one,
from miRNA elements of yi2 to gene elements of yi1; and (3) a within-gene integration layer
between copy number elements of yi3 and methylation elements of yi4 and their matching gene
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element in yi1. Therefore, the graph represented by A?miEMC simultaneously provides for causal
relationships between genes due to the signaling pathway; correlation between genes due to
miRNA-gene targeting; and reduces the statistical noise associated with observations of gene
expression by removing effects due to epigenetic and transcriptional factors. Moreover, each
of these three components is motivated by scientific understanding of the complex functional
processes that produce the observed genomic features.
For expositional clarity, we define m = (g+3p) and denote the full observation vector of m
elements by yi = (y′i1,y′i2,y′i3,y′i4)′. Writing A? ≡ A?miEMC, denote the elements of A? by δjk,
j, k = 1, . . . ,m. Depending on the location of δjk in A?, j and k may index vertices for gene
expression, miRNA expression, gene copy number, or gene methylation. Each pair of vertices
indexed by {(j, k) | δjk 6= 0} corresponds to a directed edge from yik to yij , i = 1, . . . , N .
Then, the fully-integrated NetGSA model is
yi = Λciβci + Λciγi + i, i = 1, . . . , N (2.10)
γi ∼ Nm(0m, σ2γIm) (2.11)
i ∼ Nm(0m, σ2 Im) (2.12)
where, again, ci ∈ {C,T} indexes the sample population as either control (healthy) or treat-
ment (cancer). Here, γi is a sample-level random effect.
Inference proceeds as with the expression-only NetGSA model, and the integrated EMC-
NetGSA model: We test for differential activity in subsets of the pathway features, correspond-
ing to elements in βC, βT, by indicating the features of interest in an indicator vector b. The
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NetGSA network contrast is ` = (−b · bΛC,b · bΛT), and this yields a test statistic T ∝ `β,
β = (βC′ ,βT′)′. T follows a Student’s t distribution with degrees of freedom estimated using
Satterthwaite’s approximation.
We may also characterize the miRNA integration into the network topology through a
set-theoretic lens, rather than the previous focus on the adjacency matrix. We again proceed
from a signaling pathway defined on p vertices. Denoting the set of expression nodes by VE
and the set of signaling pathway edges by EE, we characterize the signaling pathway as the
directed graph GE = {VE, EE}.
Next, we consider the set of g miRNAs known to target the p genes in VE. Denote the set
of miRNAs by Vmi, which represent observations miRNA expression, and the set of edges for
the miRNA-gene targets by Emi. The elements of Emi are directed edges defined from a miRNA
vertex in Vmi to a gene vertices in VE. Then, we may consider the integrated miRNA-expression
graph GmiE = {VmiE, EmiE}, where VmiE = VE ∪ Vmi, and EmiE = EE ∪ Emi.
For each gene, we define two additional vertices, one for methylation and the other for copy
number. Denote the sets of methylation and copy number vertices by VM and VC, respectively.
We integrate these vertices with the vertices of VE by constructing edge sets EM, EC, each of
which contains p edges. Without loss of generality, we consider a single index j = 1, . . . , p,
which relates the p gene-level observations in VEMC = VE ∪ VM ∪ VC, such that νEj ∈ VE
gives the expression vertex for gene j, νMj ∈ VM gives the methylation vertex for gene j, and
νCj ∈ VC gives the copy number vertex for gene j.
Denote the final, joint graph by GmiEMC = {VmiEMC, EmiEMC}, where VmiEMC = VE ∪Vmi ∪
VM ∪ VC and EmiEMC = EE ∪ Emi ∪ EM ∪ EC. To illustrate the integrative graph topology, we
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show in Figure 2 a toy example. In this example, we set p = 3 and g = 3. The signaling
pathway is a 2-layer binary tree that contains a root node with two child nodes. These gene
expression nodes are labeled with “G”. Two of the miRNAs target one gene each, while the
third miRNA targets all three genes. miRNAs are labeled “mi”. Finally, for each gene, the toy
graph contains one methylation vertex and one copy number vertex.
G1
G2
G3
mi1
mi2
mi3
Gene expression
miRNA expression
Methylation
Copy number
εE
εMC
εmi
Figure 2: A toy example of the integrated graph GmiEMC. White vertices (labeled “G”) are
gene expression nodes, which specify a signaling pathway topology. The three miRNA nodes
(red, labeled “mi”) target the genes, and methylation and copy number nodes integrate the
multi-platform, gene-level data (black and grey, respectively).
2.2.4 Results
First, we use a simulation study to demonstrate the improved power of our method due to
the integration of miRNA-gene target information. We then apply our method to the TCGA
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dataset for pathway analysis of the BRAF signaling pathway.
Simulations
Our simulation study follows the template of the simulations in the EMC-NetGSA paper [Zhang
et al., 2017a]. Broadly, we construct a pathway composed of a binary tree signaling pathway;
we model miRNA-gene targets that drive correlated gene expression; and we integrate the
methylation and copy number within genes. This supplies three separate layers of network
information that may contribute to gene expression, and we examine the relationship between
-omics integration and statistical power.
We modeled a signaling pathway consisting of a five-level binary tree containing 31 genes.
We integrated miRNA with directed edges from miRNA to corresponding genes. For every
gene, we added three distinct miRNA vertices, i.e., each had out-degree 1. We then partitioned
the genes in V into disjoint sets of two, proceeding from the root node. We assigned to each
pair of genes one shared miRNA, i.e., with out-degree 2. Finally, we repeated this procedure
for sets of three genes. We assigned each triplet one miRNA with out-degree 3. The network
topology for the control population signaling pathway used the same integrated binary tree
structure, with all edges in the tree’s left branch removed. For EMC-NetGSA integration, we
add to G directed edges into each gene from two vertices representing methylation and copy
number.
The network topology of the simulated binary tree is shown in Figure 3. We set the corre-
lation between expression vertices to 0.8 in the top third (two levels) of the tree; association
is 0.5 in the middle third (third level); and association 0.2 in the final third (final level).
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G13p G14p
G15p
G16p
G17p
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G23p
G24p
G25p
G26p
G27p G28p
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G30p
G31p
Gene
miRNA targets 1 gene
miRNA targets 2 genes
miRNA targets 3 genes
Methylation
Copy number
Figure 3: A simulated five-level binary tree signaling pathway. Shown is the treatment network,
which consists of: a full five-level binary tree of genes (large grey nodes); miRNA targeting 1,
2, and 3 genes (colored red, yellow, and green, respectively); and methylation and copy number
nodes (white and black, respectively). Gene “G01” corresponds to the root node, which is the
first level of the binary tree; “G02” and “G03” the second level; and so on. All integrated
edges, that is, those from miRNA, methylation, or copy number nodes, are directed into the
relevant gene node.
We set the magnitude of the association strength between miRNA and their gene targets to
0.4. In the TCGA dataset, we found that the partial correlation coefficients between miRNA
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and expression were generally symmetric. Therefore, we assigned alternating edges from miR-
NAs to genes to have positive and negative association, respectively. This may be understood
as simulating cases where miRNAs with multiple gene targets have the same sign for asso-
ciation, as well as different associations with different genes for a single miRNA. We set the
association 0.5 between copy number and gene expression, and -0.25 between methylation and
expression.
We generated observation vectors yi, i = 1, . . . , N , from the statistical model given in
Equation 2.10, where N = NC + NT. The number of control samples was NC = 50, and the
number of treatment samples was NT = 150. This reflects the imbalanced sample sizes in the
real cancer data sets. We set the variance parameters as σ2γ = 5 and σ2 = 0.5.
Denoting the mean vectors for gene expression, miRNA expression, gene copy number, and
gene methylation by βc1,βc2,βc3,βc4, we simulated two scenarios for the network-adjusted mean
parameter β. Here, c ∈ {C,T} indexes the control and treatment populations. In the first
scenario, we assigned βcj = 0, c ∈ {C,T}, j = 1, 2, 3, 4. In the second mean scenario, we held
βCj = 0 for all j. For the top two-thirds levels of the binary tree, we set (βT1 , βT2 , βT3 , βT4 ) =
(0.25, 0.5, 1.0, 0.5). In the bottom third of the binary tree, we maintained (βT1 , βT2 , βT3 , βT4 ) = 0,
as in the first scenario.
For each simulated dataset, we tested four gene sets for differential activation: (1) the full
binary tree; (2) the top third of the tree; (3) the top two thirds of the tree; and (4) the bottom
third of the tree. We estimated the miEMC-NetGSA model for the entire simulated dataset,
as well as the NetGSA variants with the adjacency matrices AmiE, AEMC, and AE, as well as
the corresponding hypothesis test for each network. We ran 1000 replicates of the simulation.
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We calculated the power for each method by the proportion of hypothesis test p-values that
were significant at the α = 0.05 level, i.e., the proportion of replicates for which we reject the
null hypothesis of no difference in pathway-adjusted mean parameters.
Figure 4 shows boxplots of the − log10 p-values from the significance tests. The left-hand
panel shows the results of the first mean scenario, in which no features are differentially ex-
pressed. The right-hand panel shows the second mean scenario, in which the top two-thirds of
the binary tree signaling pathway are differentially expressed. We compare the performance
of miEMC-NetGSA with the other integrated models described above.
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Figure 4: Boxplots of − log10 p-values from simulation study. The left-hand panel shows sig-
nificance tests for four gene sets of interest, under the first mean scenario in which no -omics
features exhibit differential activation. The right-hand panel shows the second mean scenario,
in which the top two-thirds of the simulated binary tree signaling pathway is differentially
activated, but the final third is equal in the control and treatment populations. miEMC-
NetGSA is shown in green, miE-NetGSA in yellow, EMC-NetGSA in blue, and NetGSA (“E”)
on expression only in white.
The first mean scenario permits assessment of the false positive rate under different -omics
integration schemes. We observe that in all gene sets that we tested, all four NetGSA-based
methods have low false positive rates. Most importantly, integration of miRNA with expression
alone (“miE”) does not cause an elevated the false positive rate over the original NetGSA
method. Likewise, although the false positive rate is somewhat elevated in miEMC-NetGSA, we
observe that it is not elevated significantly over the existing EMC-NetGSA method. Therefore,
we do not attribute to the miRNA integration a meaningful increase of the type I error rate.
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Further, we note that the number of miRNAs is large relative to the number of genes.
This causes the type I error rate to be lower for the methods that integrate miRNA-gene
targets, shown in the test set of the top 1/3 genes. The reason is that the larger overall
number of features provides increased accuracy to miEMC-NetGSA and miE integration, so
more substantial information is available to the inference procedure than the methods with
only gene-level network features.
The second mean scenario provides an assessment of the method’s power. We observe that
in the three test sets that contain differentially activated features, the power of models that
integrate miRNA-gene targets dominates the gene-only analyses. In fact, an integrated model
of miRNA and expression has power comparable to EMC-NetGSA integration of methylation
and copy number, although miRNA-gene expression remains under-powered relative to EMC-
NetGSA.
Also prominent is the increased power of the new method, which integrates both the
miRNA-gene targets and gene copy number and methylation. Integration of miRNA reduces
the type II error rate of the EMC-NetGSA model; equivalently, it increases the analytic power.
Finally, the miRNA methods continue to exhibit low rates of type I errors for the gene set that
is not differentially activated.
Taken in tandem, the results of the two simulation scenarios confirm the value of pathway
analysis that integrates miRNA-gene targets. We find miRNA contributes to pathway analyses
improved statistical power, relative to analyses conducted solely at the level of individual genes.
At the same time, we find that miRNA integration does not artificially elevate the false positive
rate. Finally, although the addition of miRNA to an expression-only analysis improves power,
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the increase is marginally less substantial than is provided by integrating copy number and
methylation. But, our composition of these two integration schemes achieves the highest
statistical power, and does not noticeably increase the type I error rate.
Pan-cancer analysis of the BRAF pathway
To demonstrate our procedure, we performed data analysis of the BRAF pathway, a genetic
signaling pathway previously studied by Zhang et al. [2017a]. The left-hand panel of Figure 5
shows the network topology of the BRAF pathway. It consists of 10 genes—AKT1, BRAF,
MAP2K1, MAP2K2, MAPK1, MTOR, NRAS, PIK3CA, PTEN, and RAF1—which are con-
nected by 12 directed edges. The BRAF pathway is a DAG, and this property is preserved
under integration with miRNA, copy number, and methylation.
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Figure 5: Network diagrams for the BRAF signaling pathway. The left-hand network is the
directed graph representing the BRAF genetic signaling pathway, consisting of 10 genes with
12 directed edges between. The right-hand network contains the same 10 gene vertices, but
edges represent a shared miRNA parent. In other words, two genes that share an edge are
both targets of a single miRNA, and possibly several. The graph contains 25 such edges.
miRNA-gene targets are chosen as those entries in the mirDIP database with with an “very
high” confidence score. Neither the BRAF nor MAP2K2 genes are targeted by any miRNAs.
The mirDIP database compiled by Tokar et al. [2017] aggregates predicted miRNA-gene
target relationships from several experimentally-validated sources. The database assigns each
miRNA-gene pair found across any of the 30 sources a composite integrative score. The score,
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valued on the interval [0, 1], quantifies the strength of experimental evidence that supports
the existence of the interaction. The scores are stratified by so-called “confidence classes,”
expressed in the labels “very high,” “high,” “medium”, and “low” confidence. These classes
respectively represent the top 1% of scores (very high); the next 4% of scores (high); remainder
of top 33% of scores (medium); and all other scores (low). The classes offer a discrete crite-
rion for determining whether to include in A?miEMC a specific miRNA-gene interaction. We
downloaded their mirDIP unidirectional database, version 4.1, and we considered both 3’ and
5’ UTR miRNA entries for miRNAs that were also present in the TCGA dataset.
Figure 6 shows a scatterplot of the miRNA-gene target scores from mirDIP for all genes in
the BRAF pathway. For a given gene, we identified all miRNAs in the database that target
that gene. In the figure, the scores are grouped by gene, and colored by confidence class: blue
represents very high confidence, green is high confidence, yellow is medium confidence, and red
is low confidence.
In our analysis, we used the subset of miRNA-gene targets for which the scores in Fig-
ure 6 belong to the “very high” confidence class. The right-hand panel of Figure 5 shows
the secondary graph formed between genes that are both targeted by a single miRNA parent.
Compared with the genetic signaling pathway, this secondary network has a denser edge set:
whereas the BRAF pathway contains 12 edges, the miRNA co-target graph contains 25 edges.
More generally, this larger edge set due to miRNA-gene targets indicates that miRNA
integration substantially complexifies the network structure used as input for the pathway
analysis. This contrasts with the underlying simplicity of the original graph: whereas the
signaling pathway consists of 10 genes, miRNA integration introduces to the network 238
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Figure 6: miRNA-gene interaction scores for all miRNA in TCGA dataset that target any of
the 10 genes that comprise the BRAF pathway. Scores are grouped by gene, and colored by
confidence class: very high, high, medium, and low confidence are colored blue, green, yellow,
and red, respectively. For our data analysis, we included only miRNA-gene target interactions
with “very high” confidence that the interaction exists, i.e., the blue scores.
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vertices for miRNA observations. Nearly half of these miRNAs target multiple genes in the
BRAF pathway.
The miRNA-gene target subnetwork, corresponding to the unweighted adjacency matrix
A?mi in Equation 2.9 is shown in Figure 7. This graph shows the subnetwork produced by the
directed edges from miRNA vertices to genes, based on miRNA-gene targets. The number of
miRNA targeting a given gene varies substantially, from as many as 143 miRNAs targeting
PTEN to as few as to 0. These in-degrees from miRNA vertices are given in Table 2.
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Figure 7: Topology of subnetwork of the integrated BRAF signaling pathway corresponding to
the unweighted adjacency matrix A?mi in Equation 2.9, namely, the graph formed by miRNA-
gene targets. All edges are directed from the miRNA vertex to the gene vertex. The miRNA
node colors, edge widths, and edge colors correspond to the degree of the miRNA vertex, that
is, the number of genes in the BRAF pathway targeted by a given miRNA. Grey graph nodes
are genes, while colored graph nodes are miRNAs, targeting 1 gene (red), 2 genes (yellow), 3
genes (green), 4 genes (blue), and 5 genes (purple). The genes BRAF and MAP2K2 are not
targeted by any genes. Darker edge colors correspond to higher out-degree of the associated
miRNA.
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Gene AKT1 BRAF MAP2K1 MAP2K2 MAPK1 MTOR NRAS PIK3CA PTEN RAF1
# miRNA 14 0 42 0 96 15 65 27 143 18
Table 2: In-degree by BRAF pathway gene, for edges into the gene from miRNAs. Values
count the number of edges into a given gene from any miRNA.
Although most miRNAs in the TCGA dataset target a single gene in the BRAF pathway,
47% of the miRNAs target two or more genes. In the network diagram in Figure 7, miRNAs
and their edges are colored according to the degree of the miRNA node, that is, the number
of genes in the BRAF pathway targeted by the miRNA. Although there are 128 miRNAs that
target only a single gene, the remaining 110 target multiple genes. This intricate structure is
not balanced, in neither the in-degree of gene nodes nor the out-degree of miRNA nodes. The
number of unique miRNAs that targets each gene varies from 58 (PTEN) to 4 (PIK3CA); and
while one miRNA targets 5 genes, there are 19 that target 4, 31 that target 3, and 59 that
target 2.
We obtained observations of gene expression, miRNA expression, methylation, and copy
number from TCGA, as described in Section 1.2.1 and Section 2.2.2. We considered the subset
of cancers for which all 10 BRAF pathway genes were observed, and for which more than 10
samples were available in both the tumor and normal tissue sample populations. This yielded
17 cancers for integrative pathway analysis of the BRAF pathway. The cancers and the sample
sizes we used in the analysis are given in Table 3.
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Code Cancer Tumor Normal
BLCA Bladder urothelial carcinoma 412 36
BRCA Breast invasive carcinoma 1096 161
CHOL Cholangiocarcinoma 36 15
COAD Colon adenocarcinoma 455 92
ESCA Esophageal carcinoma 185 64
HNSC Head and neck squamous cell carcinoma 528 82
KICH Kidney chromophobe renal cell carcinoma 66 57
KIRC Kidney renal clear cell carcinoma 534 427
KIRP Kidney renal papillary cell carcinoma 291 87
LIHC Liver hepatocellular carcinoma 377 87
LUAD Lung adenocarcinoma 519 182
LUSC Lung squamous cell carcinoma 504 242
PAAD Pancreatic adenocarcinoma 185 37
READ Rectum adenocarcinoma 167 17
STAD Stomach adenocarcinoma 478 132
THCA Thyroid carcinoma 507 99
UCEC Uterine corpus endometrial carcinoma 545 51
Table 3: TCGA cancer types used for BRAF signaling pathway data analysis. Given are
the TCGA cancer code abbreviation, cancer name, and sample population sizes for tumor and
normal tissue samples. Only TCGA cancers with gene expression observations for all 10 BRAF
pathway genes, as well as more than 10 samples in each population, were considered.
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Within each cancer, we performed the same four NetGSA-based pathway analyses as in
the simulation study: full integration of gene expression, miRNA expression, and gene-level
methylation and copy number (miEMC-NetGSA); integration of gene and miRNA expression
(“miE”); integration of gene expression, methylation, and copy number (EMC-NetGSA); and
the original NetGSA for expression only (“E”). To correct for the multiple comparison problem,
we adjusted p-values within each cancer using the method of Benjamini and Hochberg [1995]
(BH).
The adjusted p-values are plotted in Figure 8. The pathway is significantly disturbed at the
α = 0.05 level across all pathway methods in all cancers, with the exceptions of (1) pancreatic
adenocarcinoma (PAAD), which is not significantly disturbed under the miE analysis, and (2)
rectum adenocarcinoma (READ), which is not found significantly disturbed using any method.
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Figure 8: Results of significance tests for pathway disturbance in the BRAF pathway, across 17
TCGA cancers. Barplots give values of − log10 p-values, after Benjamini-Hochberg adjustment
for multiple comparisons. Full gene expression miRNA expression, and gene-level methylation
and copy number is shown in green (“miEMC”); integration of gene and miRNA expression is
in yellow (“miE”); integration of gene expression and gene-level methylation and copy number
is in blue (“EMC”); and the original, expression-only NetGSA results are in white (“E”). The
horizontal dotted line gives the significance threshold at the α = 0.05 level.
Although each of the methods reaches the same conclusion, using a binary decision rule
based on the p-value, in terms of the magnitude of the p-value the relative degree of significance
varies greatly by cancer. We observe that in some cancers, integration of any features other than
gene expression increased significance, and additional integrative features do not contribute
further. These cancers include bladder urothelial carcinoma (BLCA); colon adenocarcinoma
(COAD); esophageal carcinoma (ESCA); head and neck squamous cell carcinoma (HNSC);
thyroid carcinoma (THCA); and uterine corpus endometrial carcinoma (UCEC). Figure 9
shows barplots of the test statistics corresponding to the p-values. We observe that in these 6
cancers with comparable significance, the test statistics retain the same sign and approximately
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the same magnitude.
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Figure 9: Test statistics for pathway disturbance in 17 TCGA cancers, for the BRAF pathway.
Barplot heights give the test statistic value. miEMC-NetGSA is in green, miE-NetGSA in
yellow, EMC-NetGSA in blue, and NetGSA (“E”) in white.
On the other hand, for some cancers, a small p-value in the analysis of expression only in-
creases substantially with the integration of gene-level methylation and copy number, but we
do not see a corresponding increase in significance with the integration of miRNA expression
with gene expression, and in fact, we observe a decrease in significance relative to the baseline
NetGSA. Furthermore, in these situations, the full integration of gene expression, miRNA ex-
pression, and gene methylation and copy number generally has comparable significance to the
original NetGSA. The cancers that exhibit this pattern include cholangiocarcinoma (CHOL),
lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), and pancreatic ade-
nocarcinoma (PAAD). In lung adenocarcinoma, the miEMC-NetGSA method has the lowest
significance of the four methods, whereas in the other three cancers types, the new method has
significance comparable to NetGSA, if marginally higher. We observe significant downward
pressure on the test statistics for these cancers after introduction of miRNA expression, even
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causing a change in the test statistic’s sign in lung squamous cell carcinoma and pancreatic
adenocarcinoma.
Finally, we observe in the remaining six cancers—breast invasive carcinoma (BRCA), the
three kidney cancers (KICH, KIRC, KIRP), liver hepatocellular carcinoma (LIHC), and stom-
ach adenocarcinoma (STAD)— a more variable pattern. For the breast cancer, we observe
increased significance after integrating miRNAs, although the test statistics share the same
sign and remain of comparable magnitude across the methods. In kidney chromophobe re-
nal cell carcinoma (KICH), the test statistic changes sign after introduction of the miRNA
features, but retains moderate to strong significance in the integrative methods. To differ-
ent degrees, kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma
(KIRP), liver cancer, and stomach cancer each display reduction in the test statistic’s magni-
tude after miRNA integration, although they retain the same sign. Nevertheless, we observe
in three (KIRC, KIRP, LIHC) that the significance strengthens after the expansion of the
network topology to include miRNAs.
These results indicate statistically meaningful contributions of the miRNA features to the
pathway analysis, in a non-deterministic way. In some cancers, miRNA integration reinforces
the conclusions of pathway analysis using existing methods. In others, the miRNAs identify a
significant disturbance that is less apparent when the BRAF pathway is considered using only
gene-level features. This may be due to the reduction in noise at the level of gene expression
features using the augmented network, thereby accentuating the differential expression in the
pathway. Finally, in the other cancers, the reduction of gene-level noise that is accomplished by
the miRNA-gene target network effect clarifies the expression of pathway genes. Consequently,
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although we observe apparent significance in the gene-level analyses of these cancers, it is not
so much a true differential signal as it is noise attributable to common, non-genetic biological
drivers.
2.3 Discussion
Based on the simple principle of the weighted adjacency matrix and its transformation into
the influence matrix, we were able to not only model signaling pathways in terms of gene
expression, but also to integrate multiple data types at several different levels. We found that
graphical models provide flexibility in representing the relationships between various -omics
data types. Graphical models provide a useful method to relate epigenetic and transcriptomic
measurements to genetic observations, and this is readily accomplished by the EMC-NetGSA
framework. Moreover, the directedness of graph edges provides a convenient mechanism to
integrate data unidirectionally: there are known impacts of methylation and copy number
variation on gene expression, but it is not nearly as conclusive that the reverse also holds true.
Directed edges from supplementary data vertices to expression vertices permit this functional
interpretation, without exceeding known biological functions.
There is structural similarity between the miRNA and the EMC-NetGSA integration: in
both, we model an external influence directed into a signaling pathway, permitting more nu-
anced examination of the underlying network of interest. But, miRNA integration occurs at
a different level, and operates at a fundamentally distinct biological level from genes. Thus,
despite the surface-level similarities between the two integrations, they operate under different
principles, and correspond to different functional interpretations. A significant strength of
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miRNA integration is its endogenization of extra-signaling pathway correlation between genes.
That is, because individual miRNAs typically target several genes within a single signaling
pathway, miRNA integration provides a mathematical mechanism by which co-expression of
genes may be disentangled. This is accomplished in a unique manner, outside the graph topol-
ogy of the pathway itself. Integration of methylation and copy number occur not only at the
level of genes, but also entirely within a single gene: in the EMC-NetGSA model, these inte-
grated vertices do not “cross-pollinate” activity to other genes, but rather clarify the nature
of expression within a gene, conditional on its relationship to other genes. In contrast, the
miRNA integration unites components of a signaling pathway in such a way that it gives a
fuller, more holistic picture of genetic activity.
miRNA integration supplies a fuller picture of genomic activity, but that picture is far from
complete. A shortcoming of these integrated pathway analyses is their lack of dynamic interac-
tions between gene expression and the integrative graph components. Indeed, Blenkiron et al.
[2007] discuss the possibility that gene expression may in turn have implications for production
of miRNAs, and a similar argument could be made for the activity observed in methylation and
copy number. The present analyses stop short of modeling these feedback loops. But, this is
not because of a lack of modeling flexibility, and in fact, the pathway models here could easily
be extended to include directed edges from gene expression vertices into the secondary data
platform vertex sets. Rather, this lack is due to limitations in current understanding of the
biological mechanisms that give rise to copy number variation and methylation, specifically any
possible genetic cause. Nonetheless, these integrative pathway analyses anticipate the future
opportunity to construct even more detailed models of cellular and genomic activity.
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Chapter 3
Low-rank imputation of -omics
missing data
The pathway database introduced in Section 1.2.2 specify functional relationships between
genes, and correspond to a large number of -omics features in the TCGA dataset. However,
it is the case that many individual observation vectors among the N total samples in a given
cancer population exhibit missing values.
In general, statistical methods for -omics data are based on the assumption of complete data
that exhibit no missingness. In practice, datasets collected across dozens of clinical locations
on thousands of genomic features contain substantial missing data. This limits the viability
of many statistical methods, a problem that will only worsen as integrative studies become
more common. Some work has begun to look at imputation of integrative datasets. Fryett
et al. [2018] reviewed imputation methods for transcriptome data, highlighting in particular
the FUSION model [Gusev et al., 2016]. That method integrates genotype and expression,
followed by downstream analysis to identify phenotypic drivers. Several imputation schemes
were also considered, including a variant of nearest neighbors imputation, linear predictors,
and the Bayesian linear mixed models introduced by Zhou et al. [2013]. Gamazon et al. [2015]
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employed a penalized regression framework to obtain similar linear predictions.
Schulz et al. [2017] performed integrative analysis of methylation and expression data in
the human brain. For expression imputation, they use the IMPUTE model. IMPUTE [Howie
et al., 2009] uses hidden Markov models for simulation-based imputation of missing data.
Chudasama et al. [2018] also applied IMPUTE for imputation, and performed an integrative
analysis of expression and transcriptome observations in cancer.
Work on imputation for genomic pathway analysis is in the early stages. Some authors
simply introduce methodological adjustments to work around missing data. Zhao et al. [2017]
scored pathways and corrected for a deterministic impact of smaller sample sizes due to missing
data on the pathway rank. Likewise, Köksal et al. [2018] appealed to parsimony by assuming
that missing values have an insignificant effect on the overall analysis.
Other work uses predictive models for imputation: PAIRUP-MS [Hsu et al., 2019] im-
putes metabolic data for pathway analysis using a linear regression model to predict unob-
served biological signals. The Perseus -omics software [Tyanova et al., 2016] uses simulation-
based methods to obtain imputed values suitable for downstream analysis. Outside of the
genomics literature, Krause et al. [2018] imputed longitudinal data for social networks analysis
via simulation-based methods.
Dimension-reduction is also applied for imputation. Some methods based on the singular
value decomposition expression imputation [Troyanskaya et al., 2001]. Mazumder et al. [2010]
iteratively imputed missing data with a soft-thresholding algorithm. Tsuchiya et al. [2017]
used reduced-rank methods to impute values in unequally-spaced gene expression time series.
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As formulated in Chapter 2, the integrated NetGSA-style pathway analyses cannot accom-
modate any missing values. In the case of -omics features—that is, methylation and copy
number observations—that are missing, we may omit features that are entirely missing. How-
ever, for -omics features that are not missing from every sample, we may encounter a decision
between omitting samples to maximize the number of features in the analysis, or omitting
features to maximize the number of samples. The first option ignores substantial information
that may be present in the non-missing elements of samples that are missing some features.
The second option ignores substantial information that may be present in the features we omit.
The choice of the best option is at best ad-hoc, and at worst may result in significant
decreases in statistical power. To remedy persistent missing values in -omics datasets, we
employ imputation methods that leverage the low-rank nature of the full data matrix. We first
give an overview of an existing imputation method, and detail potential shortcomings of the
method. We then propose an iterative procedure that adapts the existing method. The new
procedure subsumes the existing method as a special case, and is applicable in a wider range
of scenarios, including real-world data analyses. We then perform real-world data analysis for
several integrative models, using the new imputation procedure.
Our approach enables analysis of a broader range of pathways than is possible without
imputation. This allows analysis of biological processes using all data available, not just data
that is well-formatted. In turn, this provides the opportunity to examine the organic systems
that underlie complex diseases in finer detail and greater depth. We demonstrate both these
perspectives with our data analysis: large-scale discovery among many pathways and granular
analysis of specific pathways.
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3.0.1 Structured matrix completion
Cai et al. [2016] proposed structured matrix completion (SMC) to address block-missing data.
This type of missing data arises in the TCGA dataset when a specific -omics platform was
collected at only a subset of clinical sites. The method takes advantage of the generally low
rank of the -omics data matrix, to linearly impute reasonable values for missing observations.
Denote by q the number of features in an -omics dataset of interest. For gene-level in-
tegrative pathway analysis using EMC-NetGSA, this is all expression, methylation, and copy
number features, noted in Section 1.2.1 to be q = 6973 for the TCGA dataset. However, we may
just as easily apply the method to only gene expression, or also include miRNA observations.
We format the -omics data as a q × N matrix X = (x1, . . . ,xN ), where N is the total
number of subjects. We denote by qE the number of genes with observed mRNA expression
in the dataset; qC the number of genes with copy number observed; and qM the methylation
features. In principle, a full dataset for the NCI PID would contain qE = qC = qM = 2, 393
features, for a total of 7,179 features. However, in practice, we have qE 6= qC 6= qM .
The data exhibit several patterns of missingness, particularly entire -omics platforms miss-
ing in all samples collected at specific sites, and individual -omics features with missing values
that vary according to subject, typically missing because of data quality problems.
Structured matrix completion (SMC) addresses the first of these scenarios. The method
builds on results for recovery of missing-at-random elements of low-rank matrices, for example,
Candès and Tao [2010]. The authors consider matrix X that is approximately rank r, in the
sense that its rth-largest singular value is much larger than the next; contains continuous
elements; and the matrix of deviations (X −Xr) is well-conditioned. Here, Xr is the rank-r
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singular value decomposition (SVD) approximation to X constructed using the first r singular
dimensions.
Further, suppose X is a block matrix:
X =
(
X1 X2
)
=
X11 X12
X21 X22
 (3.1)
where X22 is entirely missing. We approximate X22 using the SVD. If X were exactly rank r,
one could exactly recover X22 with the component X21X−11X12 of the Schur complement of X,
where X−11 is the Moore-Penrose pseudo-inverse. For known r but X approximately rank r, we
may recover X22 using the rank-r SVD approximation to X11,X12,X21. Finally, we choose
rˆ as the largest value of r for which the SVD approximation to X11 is non-singular, and the
approximation to X22 is well-conditioned.
This block approach works when the missing data in X has clean margins, i.e., the same
features are either all missing or all observed in all samples. However, this is not typically true
of real-world datasets, in which some subjects are naturally missing a small number of non-
overlapping features. A direct solution is to form X22 as be the minimal covering submatrix
for all missing values. When the number of observed values in X22 is small, we may justify
discarding small portions of data prior to imputation, especially when the entire dataset at
large is of interest, as opposed to individual features.
In real-world data matrices, however, the missingness in X22 is sparse. In our TCGA
dataset, for example, less than 5% of its elements are missing. The dimensions of X22 must
extend to cover all features with missing values, even those that are observed in most samples.
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In the pathway analysis framework, X is a composite matrix of data generated from multiple
signaling pathways. It is thus important to maximize the amount of information we use when
imputing each given feature, so that we do not discard information of importance to a specific
subset of pathway features of interest.
Also of critical importance is the assumption that X12 is non-degenerate, i.e., has a positive
(nonzero) number of rows. This assumption requires the presence of at least some features
observed in all samples, which is not generally guaranteed in -omics studies. We demonstrate
a toy example, below, that illustrates this case.
3.1 Integrated iterative imputation
To address these limitations of SMC, we perform an iterative imputation independently across
each sample. In the notation of (3.1), and without loss of generality, X1 is q×N1, N1 < N , and
contains no missing values; and X2 is q×N2. Here, N1 is the number of samples with complete
observations for all q genomic features, while N2 is the number of samples with any missing
values, N1 + N2 = N . Suppose further that q1 × N2 matrix X12 contains no missing values,
and X22 is the q2 × N2 minimal covering submatrix for all missing values in X, q1 + q2 = q.
q1 ≥ 0 is the number of features with no missing values, and may equal to zero, in which case
every row of matrix X2 contains at least one missing value, so that X2 ≡ X22.
We may then consider individual columns xi of X2, i = N1 + 1, . . . , N , each of which is a
sample with complete observations on at least q1 features. Of the elements of xi, we denote
by qi ≤ q2 the number of missing features.
If most of the values of X22 were missing, we might apply SMC directly, replacing the
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imputed values with observed elements of X22, where available. However, X22 is often quite
dense: in our data, more than 95% of the entries X2 are observed, so imputing all elements of
X22 with SMC risks losing possibly considerable structural information in its many nonzero
elements.
We apply SMC iteratively and independently to each of the samples in columns of X2.
Sample xi is a vector of q elements, i = N1 + 1, . . . , N . By invariance of the singular values
of X under row and column permutations, we may suppose without loss of generality that
the first (q − qi) elements of xi are entirely observed, so that the matrix
(
X1 xi
)
is entirely
observed except for a missing qi × 1 submatrix in its lower-right corner.
Turning our attention to the remaining columns of X2, we identify all 0 ≤ ki ≤ N2 − 1
other xi′ with complete observed values for the (q − qi) features observed in xi. Denoting the
index set for these vectors by {ωin}kin=1, we form the matrix
χi =
(
X1 xi xωi1 . . . xωiki
)
(3.2)
χi is q × (N1 + ki + 1) matrix, and we treat the entire lower-right qi × (ki + 1) submatrix as
missing. The first column of that submatrix, which corresponds to the missing elements in
xi, is entirely missing. Subsequent columns come from X2 and are missing a subset, possibly
improper, of the same missing values in xi. We impute this corner matrix using SMC and use
the first column to form imputed vector x̂i.
We repeat this procedure for all i = 1, . . . , N2, at the end of which, we have an imputed
matrix X̂2 =
(
x̂1 . . . x̂N
)
which contains no missing values. In turn, this yields an imputed
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matrix X̂ =
(
X1 X̂2
)
.
As a toy example to demonstrate the procedure, we consider a matrix with elements that
equal to 1, or are missing (denoted “-”):
X =
(
x1 x2 x3 x4 x5
)
=

1 1 1 - 1
1 1 - - -
1 1 - 1 1

(3.3)
We observe that, as originally proposed, SMC is unable to directly impute any of the missing
values in x3, x4, x5, because none of the rows of X is completely observed.
Figure 10 displays the configuration of X, as well as the corresponding χi, i = 3, 4, 5. x5
contains a single missing value, which is a subset of the missing elements in x3, whereas x4 is
missing that element. So, k3 = 1, and we impute the missing values in x3, using the element in
x5 corresponding to the observed value in x3; but we ignore the observed element in x5 that is
missing in x3 and x4, so k5 = 0. Implicitly, we impute this value of x5, as well, but we discard
this value, and keep only the imputed values for x3. A symmetric argument applies to x4.
On the other hand, because both x3 and x4 are missing elements that are observed in x5,
we cannot use either of these in imputing the missing value in x5.
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x1 x2 x3 x4 x5
X
x1 x2 x3 x5
χ3
x1 x2 x4 x5
χ4
x1 x2 x5
χ5
Observed
Missing
Treated as
missing
Figure 10: Iterative integrated imputation with a toy example. X is a data matrix of 5
observation vectors with missing values that do not form a rectangle. Iteratively for each
column with missing elements xi (i = 3, 4, 5), we apply structured matrix completion to the
matrix χi, consisting of all complete data vectors; xi; and any columns with missing values
that are a subset of those missing from xi. Imputation is performed on the entire rectangular
submatrix of all features missing in xi, with any observed elements not from xi treated as
missing. So, imputing x3 and x4 uses x5, whereas x5 is imputed using only the complete data
vectors.
An appealing property of our iterative imputation procedure arises when the missing data
has a block structure, as in the original SMC setting. In that case, iterative imputation
produces identical imputed values to those from SMC. Moreover, as demonstrated in our toy
example, we may apply our procedure to matrices for which q1 = 0, that is, no features are
fully observed across all subjects. In contrast, SMC cannot be used to impute that type of
matrix.
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3.2 Results
Applied to large-scale datasets, iterative imputation produces a complete matrix X̂, using
which we perform downstream analysis of pathway disturbance. We explore the power of our
two-stage imputation and pathway analysis using a simulation. Then, we apply the method
to breast cancer data to analyze pathway disturbances by tumor subtype.
3.2.1 Simulations
We follow a similar simulation design to that of Zhang et al. [2017a]. For the treatment group,
we construct a five-level binary tree. The control group network derives from the treatment
network, with all edges in the left branch (including the root) removed. Correlation between
expression vertices is set to 0.8 in the tree’s top third (two levels); the middle third (third level)
has association 0.5; and the lower third (last level) has association 0.2. We also add vertices for
methylation and copy number, integrated via directed edges to the expression vertex. We set
correlation of expression with copy number to 0.5, and correlation with methylation to -0.25.
We generate integrated data vectors yi, i = 1, . . . , N , from the EMC-NetGSA model in
Equation 2.5, where N = NT + NC. NT (NC) is the number of treatment (control) samples.
We set σ2γ = 5, σ2 = 0.5, and NC = 50 and NT = 150. We consider four gene sets:
1. All genes in the network;
2. Top one-third levels of the tree;
3. First two-thirds levels of the tree;
4. The last level of the tree.
59
Denote by βC1,βC2,βC3, the mean vectors of gene expression, copy number, and methyla-
tion, respectively, in the control population. The treatment population is defined analogously.
We simulate two scenarios for the network-adjusted mean coefficient β:
1. βT1 = βC1 = βT2 = βC2 = βT3 = βC3 = 0;
2. βT1 = 0.251, βT2 = 11, βT3 = 0.51 for top two-thirds levels, otherwise same as first
scenario.
The TCGA dataset displays missingness of two types. The first is block-wise missing data
in samples collected at specific research sites for entire classes of measurements. This type
of missing data motivated the original SMC method, and as noted previously, our iterative
imputation is identical to SMC in the special case that the missingness in X forms a block.
The second type of missingness varies the specific features that are missing within any
single sample. In this case, the SMC procedure cannot simultaneously impute all missing
values and use all observed data points. We note that the missingness does not alter the
low-rank structure of the matrix. Therefore, we designed our simulation to mimic this variety
of missingness, namely, where the features with missing values vary by sample, but we also
include block-wise missingness, as well. This allows us to compare the novel aspect of our
iterative imputation with the performance of the original formulation of SMC.
Within each simulation replicate, we generated a full data matrix, X. We randomly selected
subsets of features and subjects to exhibit missing data, giving a data matrix with missing
values. Additionally, we removed a full rectangular submatrix, which reflects the composition
of missing data that is sometimes observed. We removed all samples with missing observations
to form X˜. Finally, we iteratively imputed the missing values to obtain X̂. For comparison, we
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also imputed the matrix using SMC on the covering submatrix X22, as well as the K-nearest
neighbors (KNN) method taking median among K = 10 nearest neighbors, as implemented in
bnstruct [Franzin et al., 2017].
We performed 1000 simulation replicates for each mean scenario. We performed NetGSA
on all five data matrices for both mean scenarios, and we calculated the power for each test
by checking the significance of the Benjamini-Hochberg (BH) adjusted p-value [Benjamini and
Hochberg, 1995], at the α = 0.05 level. The power is then the proportion of simulations in
which the null hypothesis of no difference is rejected.
Our combination of mean scenarios and gene sets provides simulations in which all genes
in a gene set are differential; some (but not all) genes are differential; and none of the genes
are differential. Moreover, our simulation scenario includes missing data that is characteristic
of the real data, with a composition of data that is missing in block form, as well as data
that is missing on a by-feature basis within individual samples. This simulation setting more
accurately characterizes the real-world missing data, but this type of by-feature missingness
was not considered by the authors of SMC.
The left panel of Figure 11 gives boxplots of − log10(p) for the p-values in the first mean
scenario, in which the expression coefficients are equal across the two populations. The power
of the pathway analysis that uses our imputed matrix X̂ is comparable to that of the true
data. Our procedure corresponds to a minor increase in the type I error rate over the true
data. In comparison, direct application of SMC to the minimal covering submatrix for the
missing values results in a higher false positive rate.
The right panel of Figure 11 displays simulation significance results from the second mean
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Figure 11: Boxplots of − log10(p)-values for simulation study tests of pathway disturbance.
Network structure is a binary tree. X (shown in blue) represents EMC-NetGSA applied to
the complete data matrix, with no missing values. X˜ is the matrix with all samples with any
missing values dropped. I3 (in green) refers to our integrated, iteratively imputed matrix. SMC
uses imputed values obtained by treating the entire minimal covering submatrix as missing, and
KNN is K = 10-nearest neighbors imputation. Horizontal line gives − log10(0.05). Scenario 1
(left): No features differential. Scenario 2 (right): Top 2/3 features differential.
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scenario, in which the top 2/3 levels of nodes in the binary tree are differentially expressed.
Our iterative integrated imputation procedure exhibits power comparable to that of the true
data, and consistently dominates use of the truncated data, X˜. Application of SMC to a
rectangular submatrix is similar, but with a higher rate of false positives. In turn, this results
in power that is higher than the true data, because of the inflated propensity to reject the null
hypothesis.
KNN is comparable to our iterative imputation, but with weaker power. This relative
performance of KNN to our method is robust to a range of K, both large and small. A benefit
of our method is that the imputed values do not change the outcome of inference, as compared
with the true data. The KNN imputation uses real observed values from other observations
that are “close.” In contrast, the SVD-based methods construct a (linear) functional model for
the data, and can thus directly predict the missing values.
The direct application of SMC to the minimal covering submatrix of the missing data
in X is similar to our iterative method, but with a higher false positive rate. The elevated
false discovery rate reflects that SMC accentuates statistical noise, thereby reinforcing and
strengthening spurious deviations due to statistical variation. SMC propagates dominant low-
rank structure in X. But, discarding the information contained in samples with missing values
results in an over-emphasis of features that are not reflective of the overall data matrix. This
occurs even when imputing across a data matrix for which the mean structure is the same
across all subjects, as in the first mean scenario.
Our imputation leverages the imputation using linear dependence due to the underlying
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SMC method, while also maximizing the available information about each sample. This pro-
vides a more nuanced and complete picture of the linear structure of the network data. For
pathway analysis, it is particularly important that any imputed values be locally accurate. The
features in the TCGA data matrix X, discussed below, encompass hundreds of different path-
ways, so the matrix-wide contamination we observed in the SMC simulations poses a serious
obstacle to valid statistical inference.
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Figure 12: Simulation results for missing data in a rectangular submatrix, using the second
mean scenario in which the top 2/3 of binary tree nodes are differentially expressed. In this
special case, our iterative imputation method (I3, in green) has identical power to that of the
basic SMC method.
These results are robust to variations in the combination of block-wise and at-random
missingness. The balance between these two types may vary by dataset: for instance, the
original SMC method was designed for block-missing data from the TCGA study, but our data
analysis indicates that at-random missing values are also widespread within individual subjects.
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As the missingness progresses from at-random to block-wise, we find that the performance of
SMC improves relative to the iterative imputation. Equivalent power is achieved when the
missing data is fully rectangular, which reflects that our method gives the same result as SMC
for this edge case. This power is shown in Figure 12. However, when the data composes both
block-wise and at-random missingness, our method offers improved control of false discoveries,
without a cost in terms of power.
Finally, we note that real-world data matrices, as in the TCGA dataset we analyze, the
features in X may be drawn from many different pathways, some of which may exhibit distur-
bance in tumor samples, but others of which may have equal means in the sample populations.
This is reflected in the fourth test set in the second simulation scenario. The genes of interest
in the test set are not differentially expressed, although other features in the data matrix do
feature different means. Our iterative method identifies the differential structure in the regions
of the data matrix, without a corresponding increase in false positives. If the minimal covering
submatrix for the missing values contains all features that are differentially expressed, in the
samples with the pathway disturbance, the original SMC method will fail to reveal any path-
way disturbance. On the other hand, our method will use the partial information available in
each sample, thereby retaining the differential structure in the imputed values it returns.
3.2.2 EMC-NetGSA
Breast cancer subtype analysis
To demonstrate the value of the imputed data in pathway analysis, compared with the trun-
cated data, we performed an analysis of pathway disturbances in breast tumor subtypes.
65
Our TCGA dataset contained 838 tissue samples. After downloading the NCI Pathway
Interaction Database (PID) using the graphite software [Sales et al., 2018], which spans 2,393
genes across 212 pathways, the matrix X had q = 6, 973 rows (genomic features), observed on
N = 838 tissue samples.
It might be possible to impute the tumor and healthy sample populations as separate ma-
trices. However, a major limitation of the TCGA datasets is imbalanced sample sizes, relative
to the large number of features. This could result in sensitivity of the imputed values in the
control population, and may be unnecessary. In principle, healthy and tumorous tissues should
share many structural characteristics, namely, all non-malignant signaling activity. Therefore,
we impute both populations jointly.
Of the 838 samples, N2 = 719 samples contained missing values (681 tumor, 38 healthy),
spread across q2 = 171 features. 157 features measured copy number, and the other 14 mea-
sured methylation. The values ki, giving the number of additional columns of X2 used in
forming χi, were generally quite high: only 6 columns used fewer than 50 other samples for
imputation, or less than 1% of the total number of columns we imputed. Our imputation
procedure uses a substantial amount of the non-missing information contained in X22 when
forming χi, despite our separate imputation of each column of X2.
A key assumption of the SMC imputation method is that the data matrix is approximately
low rank. Conceptually, the data satisfy the low-rank assumption: within each population,
conditional on the subject-level random effects, the mean matrix is simply noisy observations
of a rank 1 matrix. We verified empirically the low-rank structure of the submatrix X1, i.e.,
all rows with no missing values.
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Breast tumors are known to stratify into well-differentiated subtypes [Eroles et al., 2012]. In
particular, immunohistochemical (IHC) characteristics of estrogen receptor (ER), progesterone
receptor (PR), HER2, and Ki67 are used to define intrinsic molecular subtypes [Dai et al., 2015].
Classification of tumors by subtype is useful because of substantial variation in prognosis
and behavior, with corresponding implications for survival outcomes and treatments of the
various subtypes [Feng et al., 2018]. The subtypes are strongly associated with tumor grade,
clinical outcome, and overall subtype prevalence. It is therefore critical to understand the
distinctions between separate tumor types, which may operate under substantially different
biological mechanisms.
To determine the breast tumor intrinsic subtype, we followed the classification given in
Dai et al. [2015]. These subtypes are defined according to immunohistochemistry (IHC) status
of several specific genes: ER, PR, HER2, and KI67. The TCGA dataset contains the IHC
status for ER, PR, and HER2, but not KI67, so we employ four tumor subtypes: luminal A
/ HER2- luminal B; HER2+ luminal B; HER2 over-expression; and basal, or triple negative.
The specific immunohistochemical criteria used is given in Table 4. We categorized tumors
described as “normal-like” as luminal A / HER2- luminal B, since they cannot be distinguished
on the basis of ER, PR, and HER2 IHC status. Also, we note that in the literature, it is also
conventional to refer to basal-like tumors as triple negative, based on their molecular signatures
with respect to ER, PR, and HER2.
Although we were unable to distinguish tumors on the basis of KI67, this reflected practical
considerations that apply beyond the current study. Indeed, Cheang et al. [2009] note that
“Ki67 is not included in routine clinical decision-making because of a lack of clarity regarding
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Table 4: Breast tumor subtype definitions and prevalence in data from The Cancer Genome
Atlas (TCGA). IHC status refers to immunohistochemical status for the three specified genes.
Prevalence measures a proportion.
Subtype Luminal A / HER2- luminal B HER2+ Luminal B HER2 over-expression Basal
IHC status ER+ or PR+, HER2- ER+ or PR+, HER2+ ER-, PR-, HER2+ ER-, PR-, HER2-
Tumor subtype population characteristics from Dai et al. [2015]
Prevalence 0.62 0.14 0.11 0.12
Tumor grade 1, 2, 3 2, 3 2, 3 3
Outcome Good, Intermediate Intermediate, Poor Poor Poor
TCGA breast cancer tumor sample population
Count 307 74 17 81
Prevalence 0.64 0.15 0.04 0.17
how Ki67 measurements should influence clinical decisions.” In the BRCA dataset, 479 samples
had IHC status available for ER, PR, and HER. Frequency and prevalence of the subtypes is
given in Table 4, and clearly matches that in Dai et al. [2015].
We applied EMC-NetGSA to the raw and imputed datasets for 176 of the 212 NCI path-
ways. In the remaining 36 pathways, our dataset was missing expression observations across
all subjects for at least one gene, so we were unable to analyze these pathways. We applied
the BH adjustment to the pathway-level p-values.
We ranked the pathways by the variance between the − log10(p)-values in the 4 subtypes.
We considered the five pathways that exhibited the highest variability, which reflects major
differences in the disturbance of these pathways between subtypes. These most-variable path-
ways were (1) EPHB forward signaling, (2) FOXA2 and FOXA3 transcription factor networks,
(3) ErbB2/ErbB3 signaling events, (4) Validated nuclear estrogen receptor alpha network, and
(5) E2F transcription factor network. The nuclear estrogen receptor network contains known
oncogenes and plays an established role in breast cancer [Sommer and Fuqua, 2001], as does
EPHB [Pasquale, 2010], [Kaenel et al., 2012]. But while the role of E2F is established in cancers
such as retinal cancer [Nevins, 2001], its possible role in breast cancer has only been explored
recently [Johnson et al., 2016]. This is also true of ErbB2/ErbB3 [Ma et al., 2014a], and while
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Figure 13: − log10(p)-values for integrative tests of network disturbance in genetic signaling
pathways. Shown are pathways that changed significance after imputation in at least one
sample population. Separate differential analyses were performed for each of four breast cancer
subtypes, as well as a composite population of all tumors.
FOXA1 is implicated in breast cancer [Bochkis et al., 2012], this is not true of FOXA2 and
FOXA3.
We identified the pathways for which the test for overall pathway disturbance changed
significance between the raw and imputed datasets in at least one subtype. This resulted
in ten pathways with different statistical conclusions between the raw and imputed datasets.
Figure 13 shows the − log10(p)-values for the raw and imputed datasets in these pathways,
across the different subtypes.
Changes in significance are in some cases minimal, and likely represent insubstantial sta-
tistical variation—for example, significance in any subtype is questionable in the HIV-1 and
HDAC1-mediated signaling events. Likewise, β1 integrin cell surface interactions appear sig-
nificant only in luminal B subtypes, and β2 integrin cell surface interactions is significant in
HER2 over-expression subtypes. In these cases, the significance is strong in both the raw and
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imputed datasets. Moreover, we verified the robustness of the pathways shown in Figure 13
with SMC on the entirety of X11, as well as KNN imputation, and in both cases, the same
pathways changed significance, with similar conclusions.
Of the pathways we tested, regulation of Smad2 and Smad3 signaling was identified as
significantly disturbed across all subtypes, although only marginally so for luminal subtypes;
and the pathway contains ESR1, an oncogene implicated in breast cancer. Smad2 and Smad3
play a well-established role in transcription growth factor β (TGF-β; Brown et al., 2007), and
we considered this regulatory pathway for further analysis.
Our data contained a total of N = 479 breast tumor samples with valid IHC observations.
The Smad2 / Smad3 signaling pathway consists of 68 genes, comprising 200 -omics features
after integration of copy number and methylation data. We performed NetGSA on the raw and
imputed datasets, which contained 371 and 543 samples, respectively. Of the 172 samples with
imputation, 119 were luminal A / HER2- luminal B subtype; 23 were luminal B; 6 were HER2
over-expression; and 24 were basal. We conducted significance tests for the full pathway, as
well as each integrated triplet corresponding to one gene: three nodes, one for each integrated
platform.
The network topology for the pathway consists of 423 directed edges between the expression
nodes, as well as two directed edges for each expression node to integrate copy number and
methylation, where available.
Figure 14 plots p-values for all breast cancer samples, as well as individual subtypes. Com-
parison is given between the raw and imputed datasets. Shown are the results of testing the
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Figure 14: − log10(p)-values for significance tests of integrated genomics data for the entire
Smad2 / Smad3 signaling pathway and selected genes, by subtype. Gene-level significance
tests considered integrated triplets of pathway nodes, namely, expression, copy number, and
methylation observations for each gene.
entire pathway, as well as selected individual genes, with Bonferroni testing for multiple cor-
rection. Gene-level significance tests considered gene-level trios of pathway vertices, namely,
those for expression, copy number, and methylation.
We note that, tested across all tumors, the pathway is only marginally significant. In
contrast, analyzed at the subtype level, a clean partition is clear: Smad2 and Smad3 regulation
is disturbed in HER2 over-expression and basal subtypes, with strong statistical significance,
but not disturbed significantly in either luminal A or B subtypes. These results are consistent
between the raw and imputed datasets, but exhibit stronger significance in the imputed dataset.
Considered more granularly, TG-interacting factor 1 (TGIF1) displays only marginal sig-
nificance in HER2 over-expression subtypes, consistent with the low significance of TGIF2.
TGIF2 is strongly significant in the other three subtypes, but in the raw data, TGIF1 is
strongly significant only in basal subtypes. However, our imputed method identifies these as
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Figure 15: Coefficient estimates for expression in the Smad2 / Smad3 signaling pathway, by
subtype. Selected genes shown only. Coefficients were estimated separately by population
(cancerous tumor and healthy control). Within the tumor population, separate estimates were
obtained using the raw data with missing data removed, and using the imputed data.
significantly disturbed in luminal subtypes.
Our imputation method also reveals disturbance in Smad3 in luminal A / HER2- luminal
B subtypes, and reinforces the lack of significance in basal tumors. The effect of Smad2 is
reduced in luminal B tumors but increased in luminal A.
Across all subtypes, MED15 is not identified as disturbed, but within each subtype it
is. This suggests a biological difference between the role this gene places in different sub-
types. Figure 15 shows gene expression coefficient estimates β̂ from the NetGSA analysis,
and MED15 demonstrates down-regulation in HER2 over-expressed tumors, compared with
up-regulation in basal tumors. Luminal B and basal tumors have comparable, mid-level ex-
pression in CEBPB, small in comparison with control; in HER2 over-expressed tumors, this
value is under-expressed, whereas in luminal A tumors it is over-expressed.
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HER2 over-expressed tumors exhibit expression in MYC in the opposite direction of the
other subtypes, while the imputation actually causes a change in the sign of HDAC1 in luminal
B tumors. Recent work found inconclusive results on the role of this gene in cancer tumors
[Tang et al., 2015]. The sign switch is only in luminal B tumors, whereas in other tumors the
difference is absent, or at least more muted.
Also of note is the HER2 over-expression subtype. The sample size for this subtype is
already small, at 17, but with the raw data, only 11 samples are available for analysis of HER2
over-expression. We observed sign changes between the raw and imputed data among several
genes in this subtype, including the gene CDKN1A, FOXH1, and MEF2C. The latter two
genes are only marginally significant, especially compared with the very large p-values in other
subtypes. But CDKN1A is strongly significant, and is known to relate to Smad signaling.
Smad3 is known to inhibit tumor cell growth [Zelivianski et al., 2010], but phosphoryla-
tion by CDK prevents this tumor-suppressive behavior [Liu, 2011]. Counteracting this effect,
inhibiting CDK promotes transcription by Smad3, with the effect of suppressing cancer cell
growth. This is speculated to reflect a non-canonical interaction between CDK and Smad3
that promotes tumor growth [Tarasewicz et al., 2014].
Addressing a lack of bio-marker targets for basal (triple-negative) breast tumors, recent re-
search on this subtype has considered targeted suppression of CDK phosphorylation of Smad3.
In particular, CDK has been observed to mediate a malignant interaction between Pin1 and
Smad3 that increases proliferation of cancer cells in aggressive breast tumors [Thomas et al.,
2017]. Targeted inhibition of CDK2 and CDK4 was prevented the Pin1-Smad3 interaction in
basal subtypes, confirming the finding in [Tarasewicz et al., 2014] that suppression of CDK2/4
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Figure 16: Expression coefficient estimates for a selected subset of Smad2 / Smad3 signaling
pathway genes, by subtype. Coefficients were estimated separately by population (cancerous
tumor and healthy control). Within the tumor population, separate estimates were obtained
using the raw data with missing data removed, and using the imputed data.
leads to increased Smad3 activity in basal subtypes.
Figure 16 shows expression coefficient estimates for the four tumor subtypes, for CDKN1A,
CDKN2B, and Smad3. CDKN1A inhibits CDK2 phosphorylation of Smad3, while CDKN2B
inhibits CDK4 [Driver et al., 2008]. In the healthy control tissue, CDKN1A expression is
strong, whereas CDKN2B and Smad3 are not expressed at all.
We observe negative expression in Smad3 in the basal subtype, and the same in luminal
A / HER2- luminal B tumors. This compares with slight positive expression of Smad3 in
the other two subtypes. All four subtypes display positive expression for CDKN1A, which
inhibits CDK2, however, the luminal and HER2 over-expression subtypes all display negative
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expression for CDKN2B, with the strongest effect in luminal B tumors. This corresponds to
small, positive expression in Smad3.
For comparison, we also analyzed the pathway using NetGSA on only expression data; with
integration of only one of methylation and copy number at a time; and GSEA of expression [Wu
et al., 2010]. The GSEA analysis identified only differential expression in HER2+ subtypes.
The other three NetGSA methods were strongly significant in HER2+ and basal subtypes,
as well as across all tumor types. However, while all four methods found marginal to no
significance in luminal subtypes, the EC-NetGSA exhibited stronger significance. This supports
the premise that Smad2 and Smad3 are central to transcription.
Taken as a whole, the results of our data analysis give strong support to the value of sub-
type analysis in complex diseases such as cancer. Among breast tumors, we identify Smad2
and Smad3 signaling pathway disturbance in basal and HER2 over-expression subtypes, with
weaker disturbance in luminal subtypes. We identify separate roles of Smad3 in basal and
HER2 over-expressed subtypes, suggesting the gene-level mechanism for the pathway distur-
bance may differ in the two subtypes.
Pan-cancer analysis
Following the EMC-NetGSA model of [Zhang et al., 2017a] discussed in greater detail in
Section 2.1, we constructed for each signaling pathway in the PID a directed graph, with edges
representing functional relationships connecting the corresponding vertices for gene expression.
We also introduced graph vertices for gene-level methylation and copy number, with directed
edges connecting each to the gene’s expression vertex. We estimated association weights for
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the graph edges within each cancer, and applied the NetGSA hypothesis test [Shojaie and
Michailidis, 2009] to test for differential activity. We tested the entire pathway for significance,
as well as the subgraphs corresponding to the three vertices available for each gene.
We considered for pathway analysis the 22 cancers listed in Table 1 that are marked with
a star (?). Of the 32 total cancers available from TCGA, these had more than 10 samples in
both the tumor and normal populations. After removing the pathways that contained genes
for which our data lacks observations of gene expression, we tested 173 of the PID pathways
across the 22 paired populations. In order to correct for possible false discoveries due to the
multiple testing problem, we used the procedure of [Benjamini and Hochberg, 1995] (BH) to
adjust all p-values within each cancer.
Figure 17 shows the − log10(p) transformation for the p-values in all pathways in all cancers.
We observe that many p-values are strongly significant: even after BH-adjustment of the 3806
hypothesis tests we performed, only 88 pathways did not have a significant p-value at the
α = 0.05 level.
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Figure 17: Shown is the − log10(p) transformation of the BH-adjusted p-values obtained for
22 TCGA cancer types among 173 NCI PID pathways. Darker colors indicate stronger signif-
icance, in terms of a smaller p-value. A white value indicates the pathway was not tested for
that cancer. We observe strong patterns of increased significance across all pathways within in-
dividual cancers, such as elevated significance in sarcoma (SARC) and thymoma (THYM) and
reduced significance in colon adenocarcinoma (COAD) and rectum adenocarcinoma (READ).
We also observe patterns in significance within pathways, across cancers, such as elevated dif-
ferential activity in B-cell receptor (BCR) signaling, and a lack of disturbance in the glypican
2 and 3 networks.
However, it is clear from the figure that there are associations among the p-values across
all cancers in specific pathways. This includes consistent disturbance in the pathways B-cell
receptor (BCR) signaling, ErbB1 downstream signaling, and transforming growth factor-beta
(TGF-beta) receptor signaling, as well as consistent lack of disturbance, as in the glypican
2 and 3 networks, and PDGF receptor signaling. Likewise, we observe systematic elevation
of p-values in some cancers, such as sarcoma (SARC) and thymoma (THYM), as well as de-
pressed significance across other cancers, including colon adenocarcinoma (COAD) and rectum
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adenocarcinoma (READ).
The high significance in some pathways is in accordance with current scientific consen-
sus. BCR signaling regulates B cell activity, and has additional downstream effects on other
pathways that promote tumor growth [Fowler and Davis, 2013]. [Burger and Wiestner, 2018]
discuss recent work to target malignancy in B cell signaling. ErbB1 plays a role related to
epidermal growth factor (EGFR), and its disturbance is known to relate to a variety of cancers:
[Roskoski Jr, 2014] found interactions in non-small cell lung cancer, colon cancer, and breast
cancer. They also discussed ErbB1-related targets for clinical treatment of tumors. TGF-beta
plays a central role in basic cellular activity [Jakowlew, 2006], and it can suppress or promote
tumorigenesis, dependent on the cell type [Massagué, 2008]. [Fabregat et al., 2014] discussed
treatments that target and inhibit malignant behavior in the TGF-beta pathway, in order to
recover normal functioning.
Too, it is reasonable to observe co-disturbance of pathways within cancers. [Iengar, 2018]
considered genes that consistently exhibit mutation across multiple cancer types, and identified
a large number of pathways to which they relate. [Leiserson et al., 2013] directly considered the
contrast between driver and passenger mutations in oncogenesis, and focus on finding multiple
drivers that coexist within individual cancers.
Among the 3684 hypothesis tests shown in Figure 17, we considered a subset of 14 pairs
of cancer and pathway that exhibited stronger significance than would appear typical for the
combination of the two. The cancer-pathway pairs we considered are listed in Table 5. We
considered 8 pathway disturbances in sarcoma, 3 in thymoma, and 1 pathway disturbance each
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for kidney renal clear cell carcinoma, ovarian serous cystadenocarcinoma, and pancreatic ade-
nocarcinoma. In both sarcoma and thymoma, disturbance of T-cell receptor (TCR) signaling
in naïve CD4+ T cells was elevated, as was ErbB1 disturbance. The remaining 9 pathways
are found in only 1 cancer.
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Cancer Pathway
Kidney renal clear cell carcinoma Coregulation of androgen receptor activity
Ovarian serous cystadenocarcinoma C-MYB transcription factor network
Pancreatic adenocarcinoma Regulation of nuclear SMAD2/3 signaling
Sarcoma BCR signaling pathway
Sarcoma Beta1 integrin cell surface interactions
Sarcoma Ceramide signaling pathway
Sarcoma ErbB1 downstream signaling
Sarcoma Neurotrophic factor-mediated Trk receptor signaling
Sarcoma Signaling events mediated by focal adhesion kinase
Sarcoma TCR signaling in naïve CD4+ T cells
Sarcoma TCR signaling in naïve CD8+ T cells
Thymoma BCR signaling pathway
Thymoma ErbB1 downstream signaling
Thymoma TCR signaling in naïve CD4+ T cells
Table 5: Pairs of cancer and pathway for which the residual from a regression of the logit(p)-
value was negative, and larger in magnitude than a Bonferroni-adjusted critical value. In
sarcoma, we observe 8 disturbed pathways; in thymoma, we observe 2 disturbed pathways;
and we observe 1 pathway disturbance in each of kidney renal clear cell carcinoma, ovarian
serous cystadenocarcinoma, and pancreatic adenocarcinoma.
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Some of the pathways in Table 5 reflect well-known drivers of the respective cancers. Dif-
ferential expression in MYB in ovarian cancer has been suspected for a long time [Barletta
et al., 1992], and some recent work has given attention to the role of C-MYB activation in
other cancers [Jin et al., 2017]. The latter study found up-regulation in non-small cell lung
cancer, a finding we corroborate—albeit to a lesser degree—in lung adenocarcinoma (LUAD),
the corresponding TCGA cancer type. The prominent significance of ErbB1 is unsurprising in
light of its known role in a wide range of cellular functions.
The significance of Trk signaling mediated by neurotrophic factor is perhaps surprising
in sarcoma, a bone cancer. But while research on this type of neural signaling is relatively
new, it does support the a tumorigenic role for Trk signaling. Increased expression in TrkB
and TrkC has been found to correlate with tumor growth in brain tumors [Lawn et al., 2015].
The brain-derived neurotrophic factor (BDNF) was found to bind to the TrkB receptor, and
elevated expression had strong downstream effects in other pathways [Meng et al., 2019]. A
Phase I clinical trial was also performed for an inhibitor of Trk in several cancer types including
sarcoma [Drilon et al., 2017]. Another study found that inhibition of Trk signaling corresponded
to improved clinical outcomes in Ewing sarcoma [Heinen et al., 2016].
Increased adhesion of shed tumor cells in the presence of focal adhesion kinase (FAK)
activation has been reported, and it is hypothesized that inhibition of FAK may yield superior
patient outcomes in a variety of cancers, including sarcoma [Perry et al., 2010]. Others observed
tumor suppression as a result of FAK inhibition [Crompton et al., 2013], and FAK inhibition-
mediated signaling was found to complement and reinforce synergistically the therapeutic
effects of Aurora kinase B inhibition in Ewing sarcoma [Wang et al., 2019b].
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The role of androgen receptors has been considered in murine tissues, including kidney tis-
sue, which exhibit a different biological effect from prostate and epididymis tissue [Pihlajamaa
et al., 2014]. That effect suggests a novel, kidney-specific role for the androgen receptor path-
way. Increased androgen receptor expression in kidney renal clear cell carcinoma was found
to correspond to improved clinical outcomes [Foersch et al., 2017], which supports earlier find-
ings that also found a possible tumor-suppressive role for androgen receptors via circadian
regulation in the kidney [Zhao et al., 2016].
3.2.3 miRNA-EMC-NetGSA analysis of breast tumor subtypes
We also performed integrative analysis of the breast tumor subtypes from Section 3.2.2 using
the miRNA pathway analysis framework presented in Section 2.2. Research on miRNA activity
and disturbance in breast tumors by subtype has gained traction in recent research. Blenkiron
et al. [2007] considered differential miRNA expression across subtypes, and identified clusters
of miRNA with coordinated differential activity. Tsai et al. [2018] found differential miRNA
activity among tumors, across patient ages. miRNAs can be used as a diagnostic tool to better
understand the molecular processes in tumors: Søkilde et al. [2019] performed clustering on
miRNA expression, which they found to emphasize and supplement more classical molecular
subtypes. In particular, they found that miRNAs that corresponded to improved survival
outcomes, a miRNA with high predictive power for HER2 expression, and improved discrimi-
natory power among luminal subtypes. Kolesnikov et al. [2016] also found value to diagnosis
of molecular intrinsic subtypes using miRNA expression as a proxy. And, given the regulatory
and target relationships exhibited by miRNAs towards genes, it is also natural to consider
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differential miRNA as it relates to gene activity. Oztemur Islakoglu et al. [2018] considered
the relationship between miRNAs and genes constituting the PI3K-Akt and p53 pathways.
As a source of signaling pathway topologies, we used the PID pathways. For miRNA-gene
target relationships, we used the mirDIP database. We used the breast invasive carcinoma
dataset (BRCA), with iterative imputation performed on a matrix all -omics features that we
consider in the analysis: gene expression, methylation, and copy number for all genes in the
PID pathways, as well as miRNA expression features for all miRNAs targeting any gene in
any pathway.
As mentioned above, the TCGA dataset contains IHC status for the three dominant
biomarkers of subtypes, namely, ER, PR, and HER2. In total, the breast cancer dataset
contain 1103 tumor samples, as well as 161 samples of healthy tissue. Of the tumor samples,
721 had valid IHC data. We assigned the label “other” to the remaining, unclassified samples.
Table 6 gives the sample sizes and prevalence of the tumors. We note that, with the category
for “other” removed, the sample sizes are comparable to those in the analysis of Section 3.2.2.
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Subtype Sample size Prevalence
Luminal A / HER2- luminal B 442 0.40
Luminal B 126 0.11
HER2 over-expression 37 0.03
Basal 116 0.11
Other 382 0.35
All tumors 1103
Healthy samples 161
Table 6: Breast tumor molecular subtype sample sizes and prevalence in the TCGA dataset.
Also given are the overall sample size of all tumors and healthy breast tissue.
To assess the impact of miRNA integration in the pathway analysis, we considered the
gene EPHA4, which is known to exhibiti differential activity in several cancer types [Kou and
Kandpal, 2018]. EPHA4 receptors are known to bind to ephrin B [Taylor et al., 2017]. We
observed the ephrin B reverse signaling pathway to change significance in HER2 over-expressed
tumors. Hachim et al. [2017] discussed the activation of the gene EPHA4 by different subtypes.
They found upregulation of this gene in ER+ subtypes, that is, luminal A and B subtypes, and
attribute to it transcription growth factor β-mediated cell migration. Based on this association
between EPHA4 and ER positivity, we would not expect to observe significant disturbance
in the EPHA forward signaling pathway for HER2 over-expressed subtypes. This pathway
prominently features the EPHA4 gene.
Figure 18 gives − log10(p)-values for significance tests of differential activity in the EPHA
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forward signaling pathway, across four subtypes and four integration schemes: miEMC is
miRNA-EMC-NetGSA; miE is miRNA and gene expression only; EMC is EMC-NetGSA;
and E is NetGSA on expression alone. Using the miRNA-EMC analysis, we observed strong
significance in the luminal subtypes, and slightly less so in the basal (triple negative) subtype.
As expected, HER2 over-expressed subtypes did not exhibit differential activity in the pathway.
However, the HER2 over-expressed subtypes did exhibit differential activity in the analysis of
gene-only features, and even in the miRNA-gene expression analysis.
Figure 18: − log10(p)-values for the EPHA forward signaling pathway. Axis labels indicate the
integration scheme: miEMC is miRNA-EMC-NetGSA; miE is miRNA and expression only;
EMC is EMC-NetGSA; and E is NetGSA on gene expression only.
Figure 19 displays the network-adjusted parameter estimates for the healthy and HER2
over-expression subtype tumors, under the four integration schemes. The healthy tissue pa-
rameters exhibit minor variability in magnitude across the analyses, but remain relatively
stable. In contrast, the subtype parameter values change substantially with the miRNA in-
tegration, in both magnitude and sign. Integration of only miRNA with expression caused
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substantial changes in all subtypes, although in the luminal and basal subtypes, the integra-
tion of EMC and miRNA clarifies the signs. On the other hand, the strong negative expression
of EPHA4 in the HER2 over-expressed subtypes sustains the change in sign. We also note that
the higher expression in the basal subtype is reflective of the findings of Hachim et al. [2017],
who found EPHA4 most active in basal subtypes.
Figure 19: Network-adjusted expression parameters for EPHA4 in healthy tissue and tumor
subtypes. Integration of miRNA data only substantially alters the parameter estimates for all
subtypes, in terms of both magnitude and sign. But, joint integration of miRNA, methylation,
and copy number data clarifies and highlights the difference between the ER- HER2 over-
expressed subtype and the ER+ luminal subtypes, as well as the basal subtype.
As another example, we considered the B cell receptor (BCR) signaling pathway. Wang
et al. [2019a] found that PTEN, a gene that features in this pathway, was targeted by miR-136,
which correlated strongly to poor clinical outcomes in basal (triple negative) tumor subtypes.
Qi et al. [2019] found the BCR signaling pathway to contribute strongly to basal subtype
growth. Figure 20 shows the results of significance tests for the BCR pathway under the various
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integration schemes. We observe a boosting effect due to miRNA integration in conjunction
with methylation and copy number, which applies across all subtypes, and strengthens the
evidence of pathway disturbance compared with only gene-level integration. In this setting,
miRNA integration serves less to identify a novel disturbance, and more to clarify and reinforce
the results of methylation and copy number integration. Moreover, this effect of miRNA
integration in basal tumors is supported by the literature: Hua et al. [2013] found differential
activity in the miRNAs miR-18a and miR-135b in basal subtypes, a finding which Kurozumi
et al. [2017] confirmed, as well as differential activity in miR-93 and miR-155. All four of these
miRNAs target genes in the BCR signaling pathway, which suggests a biological explanation
for the strengthened significance.
Figure 20: − log10(p)-values for the BCR pathway. Integration of miRNA data alone captures
only marginal significance in the basal subtype. But, integration of miRNA in conjunction
with gene methylation and copy number boosts the signal in basal subtypes, as well as the
others, compared with integration of methylation and copy number without miRNAs.
Finally, we also observe a super-additive effect of the two types of integration, of miRNAs
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as well as methylation and copy number. The hypoxia-inducible factor-2α (HIF-2α) transcrip-
tion factor network is understood to correlate to poor prognostic outcomes in breast tumors
[Moreno Roig et al., 2018]. Although basal subtypes are associated with this low prognosis,
Helczynska et al. [2008] found no specific correlation between the IHC status of ER or PR.
Jarman et al. [2019] found that HER2 regulates HIF-2α.
In Figure 21, we plot − log10(p)-values for the HIF-2α transcription factor network. In
the fully-integrated analysis, we observe strong significance across all subtypes. Of particular
note is the prominence of the basal subtype: this is one of the most significantly disturbed
pathways for the subtype in our study. Furthermore, the magnitude of the miRNA-EMC-
NetGSA analysis far exceeds that of miRNA or gene-level analyses. This is also true of the
luminal subtypes, but for HER2 over-expressed tumors, it is much less so. The miRNA and
gene-level integrations complement each other and provide strong support for this pathway
disturbance, despite a complete lack of significance in any subtype for the expression-only
analysis.
Figure 21: HIF-2α transcription factor network
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3.3 Discussion
Although most analytic techniques for genomic Big Data depend on the assumption of complete
data, i.e., data without missing values, it is rarely the case in practice that a large-scale -omics
dataset will exhibit high-quality observations across every feature in every sample. Far from
a shortcoming or failure for individual studies, this is a characteristic of real-world datasets
that requires sustained attention in order to enable analyses that do not simply discard data.
Low-rank methods are appealing in the context of our pathway analysis because the mean
structure of the NetGSA model is low-rank by definition. Moreover, these methods employ
structural representations of the overall data matrix, a procedure that again aligns with the
linear nature of the pathway analysis.
Despite the conceptual appeal of SMC, we found that even this method for imputation of
missing data rested upon an idealized conception of the character of missing values. Much as
statistical methods require complete data, SMC makes the unrealistic assumption that the data
matrix can be rearranged into a rectangular matrix. We found that in the TCGA dataset, the
pattern of missing values did not permit any such reordering, and use of the minimal covering
submatrix for all missing values was a dissatisfying solution because of the density of observed
values within that submatrix.
Our solution to this lack of rectangular missing data was less a new method, and more a
prescription for careful application of SMC. As noted above, our iterative application of SMC
recovers an identical imputed submatrix in the case of a missing submatrix, while permitting
application to a far broader range of datasets. More important than that edge case is the more
plausible setting in which every -omics features contains at least one missing value in some
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sample, despite global density of observations in the data matrix. In these settings, even naïve
application of SMC to the minimal covering submatrix is impossible, because this submatrix
would have full missing columns. In contrast, our applied procedure permits imputation in
these situations.
A shortcoming of our method is best illustrated by the edge case where we reproduce the
exact SMC solution: although the values are the same, the computational time to obtain
those values will be substantially longer, because we blindly perform a new imputation for
each sample that exhibits missing values. In general, we do not address composite situations
with some rectangular missing data in addition to more at-random patterns. In these cases,
computational time can be reduced substantially, by removing redundant iterations.
An innovative characteristic of our simulation study was to consider the downstream effect
of our imputation on pathway analysis that employs the imputed data. Although this style
of “full-stack” assessment is not strictly a joint analysis, in the sense that the imputation
and pathway analysis represent a single analytic step, we are able to assess the practical
value of our method. In particular, we found that our procedure imputed values that were
interior to some degree, because they did not alter the statistical decision, and particularly
did not increase the rate of false positives. More direct power analyses typically assess the
imputation’s accuracy in terms of a loss function based on the magnitude of deviations. In
some instances, this may even be the same loss against which the imputation is performed as
a minimization problem. Rather, we consider a power analysis that is conceptually orthogonal
to the mathematical characteristics of the procedure: by examining the effect of low-rank
imputation on a downstream pathway analysis, we are able to better understand the practical
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implications of imputation, rather than considering metrics divorced from actual applications.
This is not to say that our procedure offers an ultimate solution to the problem of missing
data. Indeed, as we discuss below in Chapter 5, a far superior approach would internalize the
missing values themselves into the analysis as latent variables, an approach that does not pose
any particular technical obstacles, but would unify the pathway analysis with the imputation
of missing values. This would even permit analysis of signaling pathways that contain genes
not observed in any sample, which we remain unable to solve with iterative imputation. Still,
despite the appeal of such an approach, our procedure provides an off-the-shelf way to move
past the choices that would otherwise accompany missing data. And, the overall setting of
our analysis represents a more holistic approach to considering the effects of imputation on
real-world analyses with scientific aims. We are able to emphasize the importance of statis-
tical practice, to achieve analytic goals beyond pure research, but which instead advance our
understanding of genomic activity.
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Chapter 4
Interactive data visualization and
analysis
The proliferation of -omics Big Data has produced methods that can be applied at scale. In
the preceding sections, we discussed methods for pathway analysis across a multiple sample
populations and several hundred pathways. The output of any individual pathway analysis is
large, including pathway topology, parameter estimates, and inference results. In general, the
volume of these results is difficult to manage, at best, and prohibitive of in-depth analysis, at
worst.
Moreover, statistical methods are valuable not only because of the output of a specific
analysis, but because of the wide range of analyses that are enabled. Especially for non-
technical researchers, who may lack familiarity with extensive implementation of advanced
statistical methods, it is critical not only to develop new methods and show sample outputs,
but to provide for easy, public use implementations of the methods.
In this chapter, we discuss interactive data visualization tools we developed for exploratory
analysis of the many outputs of the pathway methods we discussed. We describe a general
template for designing interactive tools using the R programming language, and illustrate
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the implementation with the output of specific analyses. We then introduce a computational
algorithm to identify subpathways that may drive differential activity in the pathways we
consider, implemented as a greedy, seed-based search. Our subpathway search may be applied
to expression data, but we also extend it to the EMC-NetGSA settings. We discuss findings
of the subpathway analysis using the TCGA dataset, and we introduce interactive software
for pathway analysis of user-supplied data. The tool also accommodates user-specified seeds,
thereby enabling a wide range of analyses.
4.1 Interactive visualization for pre-defined pathways
One use of interactive tools is to provide an interface for easy exploration of a large number
of analytic results. In particular, many model outputs can be represented visually, and the
accessibility of data visualizations is greatly improved by dynamic, interactive tools.
Some work has been done on interactive data visualization. Phandango [Hadfield et al.,
2017] provides an interactive web application for visualization of phylogenetic datasets and
analyses. General tools for interactive visualization and analysis have introduced software
packages tooled for downstream implementation of of -omics data in individual analyses [Wick-
ham, 2016, Yin et al., 2012]. The software SeqPlots [Stempor and Ahringer, 2016] implemented
novel statistical graphics for visualizing cluster analysis applied them to gene expression data.
Given the multivariate nature of our data, as well as the cross-sectional comparisons per-
formed in our inference, even straightforward analyses generate large volumes of statistical
output that requires detailed attention.
Our discussion in Section 3.2.2 of Smad2 and Smad3 signaling demonstrates this point.
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However, considered across five sub-populations compared with normal tissue, separate raw
and imputed datasets, 176 pathways, and many hypothesis tests within each pathway, it is
impractical in the extreme to generate these results “on-demand” for individual pathways, or
to manually explore thousands of procedurally-generated plots.
To address this, we implemented an interactive data visualization using the Shiny software
package in R [Chang et al., 2018]. This framework generates modern, responsive web content
from within R, with a focus on data-driven and statistical applications. Shiny does not require
direct knowledge of HTML, and provides straightforward bindings to common web elements.
Particularly useful are forms, including drop-down menus, checkboxes, and radio inputs. These
can be interacted with, updated, and modified by procedurally-generated Javascript, and sup-
plemented with text content.
Shiny operates under a client-server paradigm. The user interacts with a website, which
serves as the front-end client. A Shiny server then receives interactions and processes them on
the back-end. In implementation, the user interface and server are structured similarly, and
specify the visual interface, on the one hand, and the R-based software functionality, on the
other.
Our general template for Shiny-backed pathway visualizations contains three components:
(1) interactive graph topology of the signaling pathway; (2) output of statistical inference; (3)
model estimates. For the interactive graph topology, we use the igraph [Csardi and Nepusz,
2006] and visnetwork [B.V. et al., 2018] packages in R. igraph is software for representing and
interacting with graphs, and visnetwork provides an interactive front-end to the graphs. For
our pathway analysis, we summarize the pathway in terms of the number of features it contains,
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and offer a dynamic and interactive applet to move the graph components. Many of the
signaling pathways in the NCI PID contain a large number of edges, and static representations
of the topology obscures important aspects of the underlying network. We use color to convey
the association strength of directed edges in E , specifically, scaled according to the partial
correlation coefficient used in constructing that adjacency matrix.
The inference outputs are presented using bar plots, such as is shown in Figure 22. The
pathway analysis is from the EMC-NetGSA analysis of the breast cancer data after imputation
in Chapter 3, and indicates that integration of copy number into the pathway analysis does not
obtain increase significance, relative to an expression-only analysis, despite a large increase in
the magnitude of the test statistic. On the other hand, integration of methylation using EM-
NetGSA yields a smaller test statistic, in magnitude, but a much higher degree of statistical
significance. And, full integration using the final EMC-NetGSA model sustains the significance
of the pathway disturbance. This provides a fuller picture of the biological components that
comprise the larger biological process. Moreover, our data visualization was easy to construct,
using the R language, and easily deployed for open access, demonstrating the potential for
widespread use of similar tools to analyze and assess a large volume of analytic outputs.
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Pathway ACTN1 ARHGAP26 ARHGAP35 ARHGEF11 ARHGEF28 ARHGEF7 ASAP1 BCAR1 BMX BRAF CAPN2 CCND1 CRK DOCK1 ELMO1
Adjusted p−values for pathway and (expression, copy number, methylation) by gene
p−value is Benjamini−Hochberg adjusted across all 4 sample set tests for this pathway within each subtype. Dashed lines denote significance at level 0.05. * denotes significant p−values.
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Figure 22: − log10(p)-values (top) and signed test statistics (bottom) for the signaling events
mediated by focal adhesion kinase pathway, in sarcoma cancer tumors. These plots were
generated procedurally using an interactive data visualization application, publicly accessible
online. Shown are the results of hypothesis tests for the full pathway, as well as the -omics
features for each individual gene, tested as separate subpathways. The pathway analysis was
performed on a fully-integrated dataset consisting of expression, methylation, and copy number,
using the EMC-NetGSA model; expression and methylation (EM-NetGSA); expression and
copy number (EC-NetGSA); and expression alone (NetGSA).
These plots permit comparison of significance between different methods: for example, the
figure shows − log10(p)-values and test statistics for a signaling pathway. Color is used to enable
quick visual discrimination between methods or populations. In addition to a hypothesis test
for differential activity across all genes in the network, we also perform hypothesis tests for
individual genes. In EMC-NetGSA analyses, we consider the integrated triplets of vertices
for each gene, representing expression, methylation, and copy number. Plots are procedurally
96
generated based on the characteristics of the specific pathway. Finally, we use similar plots for
the estimated mean parameters β. The three interface components are shown in Figure 23,
based on four different analyses. The four analyses are publicly accessible online:
1. EMC-NetGSA breast cancer subtypes analysis
https://zhang-lab.shinyapps.io/pathway-analysis-missing-data/
2. EMC-NetGSA pan-cancer analysis
https://zhang-lab.shinyapps.io/pathway-analysis-tcga-cancers/
3. miRNA-EMC-NetGSA breast cancer subtypes analysis
https://zhang-lab.shinyapps.io/breast-subtypes-pathways-mirna/
4. miRNA-EMC-NetGSA pan-cancer analysis
https://zhang-lab.shinyapps.io/pathway-analysis-mirna/
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Figure 23: Interface components for interactive data visualizations. Top left: Pathway graph
topology visualization, EMC-NetGSA analysis of breast cancer subtypes. Top right: Inference
outputs: p-values and test statistics, EMC-NetGSA pan-cancer analysis. Bottom left: Co-
efficient estimates, miRNA-EMC-NetGSA analysis of breast cancer subtypes. Bottom right:
Coefficient estimates, miRNA-EMC-NetGSA pan-cancer analysis.
4.2 Interactive pathway analysis for subpathway identification
The preceding methods focus on pathway analysis for known signaling pathways. But, it is
often the case that subpathways within a larger signaling network of genes may drive differential
expression of the full pathway [Martini et al., 2012]. Indeed, individual signaling pathways have
been modeled as subpaths within a larger, trans-genome “superpathway” [Vaske et al., 2010]. It
is therefore of interest to identify specific subpaths among fuller signaling pathways to identify
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the most significant components of a larger network.
Many methods exist for subpathway discovery, from blunt and straightforward methods
to more sophisticated algorithmic approaches. He et al. [2017] gave an overview of several
methods for identifying subnetworks of interest. They found that some methods were able to
recover important subpathways in simulation studies, but failed to find any one method that
dominated others.
Exhaustive elaboration of every subpathway is so computationally difficult as to be im-
possible. Some research nonetheless considers all possible pathways: Koumakis et al. [2016],
for example, consider all possible subpaths of regulatory networks. Others reduce the compu-
tational complexity: TEAK [Judeh et al., 2012] considers linear subpathways between roots
(in-degree 0) and leafs (out-degree zero), as well as a critical path method to connect cliques
of three genes. Similarly, Nam et al. [2014] noted the combinatoric obstacle, and introduced
PATHOME to identify gene expression subpathways that partition two populations. They
started from leaf nodes, i.e. pathway vertices with in-degree equal to 0, and expanding sub-
paths on the basis of hypothesis tests for correlation coefficients.
Other approaches consider pre- or user-defined subpathways of interest, rather than emer-
gent identification of subpaths based computational search. Li et al. [2009] considered metabolic
pathways, identified based on the significance of a hypergeometric test of subpathways of inter-
est, against the full set of all pathway nodes. Subpathway-GM [Li et al., 2013] integrated gene
expression and metabolite data, and considered shortest paths connecting nodes of interest to
identify subpathways.
Seed-based methods offer a more adaptive approach to subpath discovery. Lee et al. [2017]
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proposed MIDAS, a greedy approach that proceeded from an initial seed and expanded a graph
based on the most active edges and a stopping rule based on exponential decay. Likewise, Liu
et al. [2019] performed integrated subpath discovery with a greedy algorithm. They considered
observations of expression, methylation, and copy number, and used marginal t-tests, integra-
tion via Fisher’s test, and greedy agglomeration to increase the pathway score. Like MIDAS,
they used a stopping rule based on the subpathway size, as well as a threshold for the “value
added” by expanding the subpath.
To address the lack of consensus on how to identify subpathway drivers, we propose a seed-
based, greedy algorithm that is firmly grounded in graph-theoretic pathway analysis, via the
NetGSA model. We given an overview of the basic method, applied to gene expression. Then,
we extend the method to the -omics setting, following the EMC-NetGSA integration scheme.
We demonstrate interactive visualization of the subpathway discovery. Finally, we introduce
a web application for interactive analysis, both for pathway inference as well as on-demand,
seed-based subpathway discovery.
4.2.1 Greedy algorithm
As in previous sections, we considered a signaling pathway specified in terms of a directed graph
G = {V, E}, defined across p genes. We estimated the NetGSA model given in Equation 2.10.
We performed p hypothesis tests, one for each gene in the pathway. Although the individual
hypothesis tests consider differential expression of a single gene, we emphasize that the full
NetGSA model controls for pass-through effects in the individual genes of interest from other
genes in G.
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We chose a seed gene from which to begin the analysis, based on the gene with the strongest
significance, that is, the smallest p-value from the NetGSA hypothesis test. This seed repre-
sented the initial subpathway, which contained a single gene.
We proceeded in a greedy fashion: for a given subpathway, we found all child genes of
any gene that was already part of the subpathway. For each of these child genes that are
not already in the subpathway, we formed a candidate subpathway, based on the union of the
current subpathway and the child node. We performed NetGSA hypothesis tests for each of
the candidate subpathways.
We then compared the significance of each candidate subpathway with the current subpath-
way. If any candidate subpathway exhibited stronger significance than the current subpathway,
in terms of a p-value of smaller magnitude, that candidate subpathway became the current
subpathway. If no candidate subpathway increased the significance over the current subpath-
way, we stopped, and identified the current subpathway as the driver of the overall pathway.
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This procedure is summarized in Algorithm 1.
Algorithm 1: Greedy NetGSA subpathway algorithm
Data: A graph G = {V, E}; an initial subpathway of one vertex, the seed; the seed’s
NetGSA test p-value
while Vertices in current subpathway have children not in subpathway do
Find all k child vertices of current subpathway vertices;
Form k candidate subpathways as union of 1 child and current subpathway;
Calculate k NetGSA test p-values, one for each candidate subpathway;
if Some candidate subpathway has p-value less than current subpathway then
Set current subpathway to candidate subpathway with smallest p-value;
else
break;
end
end
Result: A subpathway, as a subset of V
Extension of the method to the EMC-NetGSA -omics setting is trivial: in identifying
the seed node, we consider the test set for an “individual” gene to consist of the triplet of
expression, methylation, and copy number nodes for that gene. Similarly, in forming candidate
subpathways, we include all three nodes for each child gene. Child genes are chosen only from
the main signaling pathway, although the testing is performed across all integrated nodes in
the graph.
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4.2.2 Algorithm performance
Care is needed in the implementation of combinatorically intensive algorithms such as this
greedy algorithm. A naïve application of the search method would estimate the pathway
model at each iteration of the search, as well as for each candidate subpathway. However,
substantial improvements can be made to run time by the relationship between the pathway
model estimation, on the one hand, and the hypothesis test, on the other. Existing imple-
mentations of the NetGSA framework provide an API with a single access point to estimation
and hypothesis testing. However, these represent two fundamentally different components and
steps of the overall analysis. All hypothesis tests can be performed using the same estimated
model, if the tests consider only subsets of the features in the estimated model. Therefore, we
produced a modified version of the NetGSA implementation that allowed us to estimate the
model once, at the beginning of the analysis, followed by greedy application of the hypothesis
test only.
To assess the performance of our greedy algorithm, we considered simulations and real-world
data analysis. For a simulation, we used a similar structure to that employed in Section 2.2 for
the miRNA-EMC-NetGSA. We used a five level binary tree for both the control and treatment
populations, with integration of methylation and copy number. We did not consider any
miRNA integration for the simulation. We again set the association between copy number and
expression to be 0.5, and association between methylation and expression to be −0.25. The
top two levels of the tree had association 0.8, the next two had association 0.5, and the final
level had association 0.2. We considered one mean scenario: the control group had mean 0,
and the left branch of the treatment group had mean values 0.25 for expression, 1.0 for copy
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number, and 0.5 for methylation. This a significant driver subpathway in the left branch of
the tree.
We ran 1000 replicates, and in each replicate, we used as the seed node the binary tree
root, which is a member of the subpathway. This was intended to allow assessment of the
degree to which the greedy subpath recovers the entire true driver subpathway. Because of
the directed binary tree structure of the simulated network, starting with a subpathway node
other than the root of the tree would deterministically prevent recovery of the full subpathway,
despite the equal means, which can be interpreted as equal pathway disturbance. Under this
simulation scheme, 80% of the time, we recovered at least half of the subpathway, and 30% of
the time, we identified 13 of the 16 subpathway nodes. In more than 5% of the simulations,
we discovered the full pathway. For the binary tree, which contained 31 genes and 93 total
features, the average run time was 0.04 seconds.
We also ran the simulation using as the seed the single most significant gene. We empha-
size that the caveats above hold: given the pathway disturbance has equal magnitude in all
features in the tree’s left branch, the gene with highest significance should follow a uniform
distribution, whereas seeding with any non-root node will prevent recovery of the node. Of
the 1000 replicates, only one single replicate contained any genes not in the true subpathway
with disturbance. On the other hand, the median of the proportion of true subpathway genes
contained in search algorithm’s output was low, at 6.25%. However, this reflects that, as the
seed node’s location in the tree proceeds from the top level to the bottom, it becomes deter-
ministically less likely that the full pathway will be included. In fact, with each level, half of
the remaining nodes become unreachable. Indeed, for the subset of subpaths that used as seed
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a gene from the top two levels of the tree, the median proportion of true subpathway genes in
the found subpathway was 0.5. Run time was identical to that in the simulations where the
subpathway was always seeded with the root node.
Together, these simulation results indicate that the subpathway method is accurate at
finding most subpathway genes, when the seed’s location is located favorably to reaching all
other subpathway genes. But, a shortcoming of the method is its strong dependence on starting
in the “right” place. As we will show below, it is possible to sidestep this issue by considering
multiple seeds, rather than only the most significant single gene.
For real-world application of our subpathway procedure, we considered the bladder urothe-
lial carcinoma dataset from TCGA, which contained 448 samples total. This was a represen-
tative sample size for most cancers in our dataset, and was somewhat larger than the mean.
Therefore, we believe the behavior of the algorithm is well-represented by application to this
dataset. To illustrate the data analysis, discussed in further detail in the next section, we
considered a full analysis of the 212 PID pathways discussed above, using EMC-NetGSA in-
tegration. After completion, we had analyzed 173 pathways, and identified subpaths within
each. The full analysis took 191 seconds, or 3 minutes and 10 seconds.
For more detailed analysis of a specific signaling pathway, we considered the pathway for
TCR signaling in naïve CD4- T cells, again in the bladder cancer data. We chose this pathway
because it contained a moderate number of genes features, 60, and had the largest subpathway
of any pathway in the bladder cancer data analysis, q = 17. We note that q corresponds directly
to the number of iterations performed before termination of the algorithm, as described in
Algorithm 1, so this served as a sort of upper bound for computation time of any network.
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This pathway was comparable in size to the largest pathway (96 genes), so we believe it is an
appropriate measure of the algorithm’s performance.
We ran the greedy algorithm 100 times for the pathway. We measured only the main loop
of the algorithm, so the run time did not include the initial estimation of the pathway model,
or estimation of the association weights. We found a 95% confidence interval for the run time
was (3.56, 3.68) seconds, with a mean of 3.62.
4.2.3 Analysis: results and visualization
We performed the iterative procedure four times, using expression-only NetGSA and EMC-
NetGSA for the breast cancer subtype dataset, as well as each of the TCGA cancer populations.
In each analysis of each pathway, we used as the seed the gene with the strongest significance.
In the pan-cancer data, across 11 cancers, we searched for subpathways for 1899 pathways.
Of these, 970 subpathways—more than half—were degenerate, in the sense that they contained
only the seed gene. Among these pathways, we identified 37 pathways for which the subpath-
way was consistent between the two NetGSA analyses, on expression data and on expression,
methylation, and copy number. Of these, five subpathways consisted of three or more genes.
These subpathways are listed in Table 7.
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Cancer Pathway p q Subpathway
BLCA Signaling events mediated by PRL 22 3 CDKN1A, PTP4A1, RHOA
BLCA Urokinase type plasminogen activator 38 4 ITGB3, ITGB5, SERPINE1, VLDLR
uPA and uPAR mediated signaling
BRCA Reelin signaling pathway 28 6 ITGB1, MAP2K7, MAPK8
NCK2, PIK3R1, RELN
LUAD EPHB forward signaling 33 3 EFNB1, MAP4K4, RAC1
THCA Presenilin action in Notch and Wnt signaling 45 3 AES, CTBP1, TLE1
Table 7: Subpathways which were consistent between the expression-only and integrated anal-
yses, and contained three or more genes. Cancers are labeled according to the codes in Table 1
(BLCA is bladder urothelial carcinoma; BRCA is breast invasive carcinoma; LUAD is lung
adenocarcinoma; and THCA is thyroid carcinoma). p gives the total number of genes in the
pathway, while q gives the number of genes in the subpathway.
As one example among these pathways, for “signaling events mediated by PRL” (PRL is the
hormone prolactin) in bladder urothelial carcinoma (BLCA), a subpathway of three genes was
found that was consistent across the two analyses. This pathway is shown in Figure 24, with
the seed (PTP4A1) shown in yellow, and the other subpathway genes in orange. Research
literature on prolactin has identified association with cancers: Sethi et al. [2012] discussed
evidence to support a relationship between the PRL and tumorigenesis, particularly in breast,
prostate, and gynecological cancers. However, they did not discuss its relation to bladder
cancer. RHOA overexpression and overabundance have long been known to correlate with
poor clinical outcomes in bladder cancer [Kamai et al., 2003]. Liu and Kwiatkowski [2015]
found widespread CDKN1A mutations in bladder cancer, and that knockdown suppression of
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its expression increased the receptiveness of the cancer to treatment.
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ITGB1RHOC
MAPK3 MAPK1
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ROCK1
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PTP4A2
CCNA2
ATF5
Figure 24: Pathway for “signaling events mediated by PRL.” The subpathway genes are shown
in yellow (seed node) and orange. This subpathway of three genes was obtained from blad-
der urothelial carcinoma (BLCA), and was identified consistently in the NetGSA and EMC-
NetGSA analyses.
We also considered subpathways that recurred across multiple pathways. As a heuristic,
we considered those subpathway that were identified exactly in multiple pathways. Table 8
gives the recurrent subpathways that were found by the EMC-NetGSA integrated subpathway
search. We highlight that the laminin subunit α gene LAMA2 was found by both Schuetz
et al. [2005] and Yang et al. [2017] to be associated with renal cell carcinoma, as well as other
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genes from the LAMA and LAMC families.
Cancer q Subpathway n
KIRP 3 LAMA2, LAMA5, LAMC1 2
LUAD 2 MAP2K1, MAPK1 2
THCA 2 SUMO1, XPO1 2
Table 8: Subpathways that recurred exactly in multiple pathways for the same cancer, under
the EMC-NetGSA analysis. Cancer gives the cancer code from Table 1 (KIRP is kidney renal
papillary cell carcinoma; LUAD is lung adenocarcinoma; THCA is thyroid carcinoma). q is the
number of genes in the subpathway, and n is the number of pathways in which the subpathway
recurred.
Finally, we also considered the individual genes that were consistently included in the
subpathways of multiple pathways, within each cancer. Figure 25 shows these genes, for both
the NetGSA and EMC-NetGSA analyses, for any gene that recurred in at least four pathways
in at least one cancer. This offers another perspective on the drivers of cancers, particularly
the individual genes that may strongly associate with the cancer, rather than the subpathways
that may drive overall pathway disturbance.
The prominence of specific genes in specific cancers is quite consistent between the two
analyses. For example, a mutation that downregulates PIK3R1 was found by Lin et al. [2015] to
correspond to increased tumor growth, as well as elevated metastasis, in kidney renal clear cell
carcinoma. Cizkova et al. [2013] identified PIK3R1 as a prognostic biomarker for breast cancer,
and Chen et al. [2018] found mutations of PIK3R1 coincided with increased tumorigenesis in
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breast cancer. FOS was found by Bakiri et al. [2017] to correlate with accelerated tumor
growth in liver cancer.
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Most frequent NetGSA subpathway genes, by cancer
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Most frequent EMC−NetGSA subpathway genes, by cancer
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Figure 25: Results of greedy algorithm for subpathway discovery, using NetGSA with expres-
sion values only (top), and integrated EMC-NetGSA (bottom). The subpathway search was
initialized using the single most significantly-disturbed gene in the pathway. The subpathway
was expanded by including adjacent genes that increased the subpathway’s significance. Counts
of gene occurrence in subpathways for any signaling pathway, organized by cancer. Only genes
that recurred in some cancer across four or more pathways are shown. Genes identified in this
manner as “drivers” were broadly consistent in the two analyses. This suggests these driver
genes contribute to subpathway activity in a robust manner, and are not merely spuriously
significant genes. Integration of methylation and copy number resulted in a larger number of
driver genes within each cancer. Moreover, these significant driver genes do not recur in the
same patterns across multiple cancers, which indicates differential functions for these genes
across different cancers.
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We published two interactive data visualizations of the subpathway analysis online, one a
pan-cancer study, the other for breast tumor subtypes. For each, we summarize results for
both EMC-NetGSA and expression-only NetGSA. The websites are located online at:
• Cancer drivers: subpathway identification among signaling pathways
https://zhang-lab-network-analysis.shinyapps.io/subpathway-analysis-pan-cancer/
• Breast cancer drivers: tumor subtype subpathway identification among signaling path-
ways
https://zhang-lab-network-analysis.shinyapps.io/subpathway-analysis-breast-tumors/
4.2.4 Interactive analysis
Individually, these findings suggest our subpathway analysis finds real drivers that underlie dif-
ferential activity observed in signaling pathways. As before, the subpathway analysis produces
a large volume of results, and for this we built an interactive visualization of the subpathways.
In particular, we used dynamic graphs to display the full pathway and the subpathway we
identified, an exploratory visualization that matches Figure 24.
However, the analysis relies upon the strong assumption that the most significant individual
gene will also be part of a driver subpathway, but there is no theoretical reason this should
be the case. This choice of seed was motivated by the intuition that strong significance of
individual genes might correspond to significantly disturbed subpathways, but is also reflective
of the computational complexity that accompanies any subpathway search.
In order to achieve more versatile subpathway identification, we implemented a tool for
interactive pathway analysis and subpathway search. Like the visualization applications, we
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used shiny to build a reactive website, including interactive graphs. To permit a wide range of
datasets not restricted to the NCI PID and TCGA samples, we provided web forms for users
to input custom pathway specifications as well as arbitrary data files.
Inputs took the form of white space-delimited text files containing an edge list, for the path-
way specification, and genomic data with identifying labels for the rows, containing genomic
features, and population labels for the columns, corresponding to samples. Upon uploading
the pathway specification, we displayed interactive network topology, and after uploading data,
we displayed population information.
We then perform the NetGSA hypothesis test for differential activity in the pathway be-
tween the two populations, and plotted the output of the statistical estimation and inference:
significance test p-values for the pathway and individual genes; test statistics; and expression
parameter estimates. This provides on-demand pathway analysis for user-provided data.
Additionally, we provided an interface to the subpathway search method. The user specifies
a seed gene of interest, and the algorithm proceeds to identify subpaths from this seed, as
described in Section 4.2.1. The analytic benefit of this interface is large: rather than restricting
the analysis to a single seed gene based on a heuristic, we provided access to subpathway
analysis using any gene in the pathway as a seed. This permits exploratory analysis of the
roles played by various components of a signaling pathway. This is particularly valuable for
pathway analysis of large pathways, which may contain multiple subpathways of interest or
with differential activity. Figure 4.2.4 shows the inputs summary page and the results of the
subpathway algorithm for the interactive analysis website.
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We published the interactive subtype analysis online at the following URL: https://
zhang-lab-network-analysis.shinyapps.io/interactive-subpathway-analysis/.
4.3 Discussion
Despite the large volume of analytic output that accompanies analysis of large-scale -omics
datasets, we found that interactive data visualization was an effective technique to make results
easy to review and explore, and also provided a convenient method to distribute the results
of statistical analysis. And, although it was previously necessary to obtain specialist skills in
web development to create interactive websites, modern tools like the R package shiny are a
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valuable resource for development of responsive and professional visualizations. In particular,
these interactive tools can be implemented without specialist knowledge of web technologies,
and can be implemented with ease by statisticians familiar with R.
We also found that the large-scale nature of many signaling pathways made it difficult to
identify specific components of those pathways that contribute to pathway activity or distur-
bance. In order to identify these “drivers” of genomic activity, we implemented a greedy search
algorithm. Our algorithm was designed for and embedded within the pathway analysis frame-
work, which was a valuable characteristic for ensuring a unified analysis. We used a greedy
procedure to identify the subpathway seed, which was an effective and reasonable choice for
initialization of the method. Because of the large number of vertices that are contained in
some pathway graphs, identification of subpathways is a combinatorically hard problem, but
the internal consistency of using NetGSA pathway analysis to identify subpathways of interest
was justified as a starting point. We found our subpathway identification algorithm had good
performance when implemented efficiently.
Still, because of the large number of possible graphs, it was not possible to perform an
exhaustive search, and we recognized that the most significant individual gene, which we used
as the subpathway seed, might not deterministically lead to the most significant subpathway.
From a theoretical perspective, using many seeds to identify many subpathways could achieve
more consistent recovery of the true subpathway with significant disturbance. This would
require integration of incompatible subpathways, which could be achieved using a consensus-
type rule that identifies subpathways that are stable across multiple seeds. From a procedural
perspective, it is important to be able to assess multiple seeds, and we applied the lessons
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learned from interactive data visualization to build a web application for interactive analysis.
Specifically, by allowing the user to select a seed for the subpathway algorithm, we obtained
a good balance between comprehensive analysis of the subpathways, and constraints on our
ability to search through every possible subgraph.
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Chapter 5
Concluding Remarks and Future
Research
5.1 Concluding Remarks
Real-world analysis of bioinformatic data requires dynamic statistical practice in multiple
stages. It can be necessary to variously remedy shortcomings of a dataset, identify biolog-
ically meaningful models of the relationships between multiple data types, and situate these
analyses in statistically valid modeling frameworks. In the previous chapters, we presented
several models for integrative pathway analysis, using data types collected for genes as well as
for non-gene functional units. These pathway methods contribute a model-based, statistically
sound procedure for integrating these -omics data types into a single pathway analysis. Al-
though integrative analysis has become much more prominent in recent years, far too often,
practitioners perform integration manually, by running separate analyses for each data type.
We hope our statistical methods will contribute to more sophisticated analysis of the functional
interactions found in the human genome.
We also addressed practical problems in performing pathway analysis on large-scale datasets.
We implemented a method for imputation of missing data, and demonstrated that it provides
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sensible values for downstream analysis. It could be possible to directly and jointly model miss-
ing values and the pathway structure, as we discuss below. But, such an approach would require
tailor-made customization for each subsequent analysis of a dataset. Rather, our method per-
mits any downstream analysis that requires complete values, thereby empowering a wide range
of analyses based on a single imputed dataset.
We also addressed the difficulty encountered by large-scale analysis of genomic Big Data,
particularly the practical difficulty of exploratory data visualization and analysis. We im-
plemented several interactive web applications to facilitate and promote analysis of -omics
datasets. Moreover, we situated an exploratory method for subpathway analysis in the inter-
active framework, as well, permitting on-demand, interactive analysis. Subpathway discovery
is a computationally intensive application, especially because of the combinatoric complexity
of even simple graphs. By presenting an analytic interface, we permit more flexible analysis of
a wide range of scenarios.
In aggregate, these methods provide a pathway model as a starting point for analysis, an
imputation procedure to maximize the applicability of the pathway analysis, and several inter-
active applications that allow exploratory visualization and analysis of the results. We believe
this presents a coherent, unified analytic pipeline that focuses on development of statistical
methods, but also addresses practical problems in data analysis. Especially for bioinformatics
datasets, the role of the statistician is not simply to develop new methods, but also to em-
power researchers to expand human knowledge in their respective fields, and we hope to have
accomplished that, at least in part, through this dissertation.
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5.2 Future Research
Research is never “complete,” one merely reaches a stopping point. This thesis is just such
a stopping point: avenues for further research sprout like the heads of a hydra in several
directions.
One direction for future work is more comprehensive integration of miRNAs. In particular,
the TCGA dataset contains not only miRNA expression, but also copy number variation.
Although biological understanding of miRNA activity is still relatively shallow, it is easy to
imagine an integration scheme similar to that of EMC-NetGSA, with directed edges from copy
number vertices to miRNA expression vertices. On the other hand, this further expansion of
the graph would result in substantial expansion of the adjacency matrix: the largest pathway
in the PID, ErbB1 downstream signaling, contains 653 features in total, of which 368 are
miRNA expression vertices. Already, the number of miRNAs is larger than the number of
gene-level features for every pathway in the PID, and integration of an additional vertex for
each miRNA would simply exacerbate this problem. Quickly, the dimension of the observation
vectors yi—equal to the number of graph vertices—may well become larger than the number
of samples, and special care must be taken in these situations.
Another opportunity for extension is to make the covariance structure of the integrative
NetGSA variants richer. In particular, the miRNA-EMC-NetGSA and EMC-NetGSA models
are parameterized with a single error variance and a single random effect variance. There is no
reason a priori to suppose that the variances are equal across data platforms, and empirically,
we observed substantial variation in the variance estimates for the same pathway under different
integration schemes. A straightforward starting point would be to stratify the variances by
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data platform, with separate variance magnitudes for each data type.
We also observed that the error variances also differ within sample populations, and even
between different features of the same data type. Therefore, it is desirable to specify a model
with a more flexible covariance structure than the isotropic error that treats the magnitude
of the variances as equal. This might be accomplished through a hierarchical linear model,
or separate error variances by individual genes. It might also be viable to employ cluster
analysis to identify coherent groups of features or samples that exhibit similar variances, with
heterogeneity between groups. More preferable would be a latent class model that internalizes
the presence of separate groups for the variances of -omics features or subjects. This model
is justified by our finding that, although there is some heterogeneity in error variance, it
empirically does not appear that the variance is different between every feature.
A third direction for further research is network regression. Despite the apparent coherence
of the NetGSA model discussed in Shojaie and Michailidis [2009, 2010], Ma et al. [2014b], we
found that the model is not identifiable. A brief simulation study illustrates the problem:
We considered a network with three nodes arranged linearly, that is, with an edge from
gene 1 to gene 2, and another from gene 2 to gene 3. Define the values σ21 = 1, σ22 = 5, β1 = 13,
and β2 = −13.
We calculated Λ1,Λ2, and generated data from two models:
1. Random effect variance σ2γ = σ21, error variance σ2 = σ22;
2. Random effect variance σ2γ = σ22, error variance σ2 = σ21.
From each population, we generated 150 observations. NetGSA produced the following
estimates of the variance components:
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Dataset σˆ2γ σ2γ σˆ2 σ2
1 5.55 1.0 1.12 5.0
2 4.59 5.0 0.90 1.0
In each, the larger magnitude is clearly allocated more to σ2γ than σ2 , regardless of the true
magnitude. This identifiability may be resolved in the mixed-models framework by using some
constraints on the relative magnitudes of σ2γ and σ2 ; further discussion on the identifiability of
linear mixed-models is given in Wang et al. [2013].
However, another approach would be to consider a fixed-effects linear model without any
random effects. Such a model would not model correlation in the errors across genes at the
level of individual samples, so we may modify this to produce a network regression:
yi = Λβ + Λi (5.1)
Rearrangement of terms, specifically under the assumption that Λ is invertible, gives the
linear means model model:
Λ−1yi = (Ip −A)yi = β + i (5.2)
We note that the arguments of Shojaie and Michailidis [2009, 2010] depend upon the
invertibility of (Ip − A) to define Λ in the first place, and employ a limit approximation to
address situations in which this is not the case. The network regression formulation would
sidestep this requirement, and still accommodate correlated errors.
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In this framework, to perform a significance test of differential activity across all genes in
the signaling pathway, we have a network contrast ` and an F statistic
` = (−1 · 1Λ1,1 · 1Λ2) (5.3)
F = (`βˆ)
2/(`(X′X)−1`′)
σˆ2
(5.4)
where, under the null hypothesis of no difference, F ∼ F1,np−2p. This is straightforward linear
model theory, and does not require substantial conceptual developments.
The network regression model formulated in Equation 5.2 is appealing. One attractive char-
acteristic is that the network regression model directly exposes the elements of the weighted
adjacency matrix A, without requiring intermediate matrix inversion prior to parameter esti-
mation. The NetGSA framework supposes the adjacency matrix association weights between
adjacent vertices are fixed and known, presumably obtained exogenously from a supplementary
source. In practice, it is not generally viable to obtain partial correlations to use as weights
except from the dataset of analysis. We typically employ a two-stage approach, estimating
first the partial correlations, then estimating the regression mixed model conditionally. In
principle, this will introduce bias into the estimation, and it would be preferable to estimate
a joint model that simultaneously estimates the adjacency weights and the activity parameter
β.
Such a joint model of the adjacency weights and the activity parameter introduces some
mathematical obstacles. First, although the influence matrix is derived from the adjacency
matrix, the interpretation of the term (Ip −A) is not entirely clear, especially in the setting
122
where Λ is obtained using the approximation of Shojaie and Michailidis [2010]. Second, many
complex signaling pathways correspond to singular unweighted adjacencies A?, in which situ-
ations the model may not be estimable. This joint model warrants further research, especially
because non-singular signaling pathway A? are available, even if not the majority.
Another direction for further research is joint modeling of the missing values directly with
the pathway analysis parameters. The linear method from Chapter 3 has a mathematical
simplicity, but the two-stage procedure may introduce bias into the estimation, and moreover,
the imputed values do not have a biological interpretation. To remedy this issue, we would
like to employ a latent variable model, in which missing gene features are imputed as part
of the model. Our pathway analyses can be understood to be structural models of biological
phenomena, and latent variables for features with missing values would embed the imputation
process fully within the functional pathway model.
Another shortcoming of our iterative imputation method is its dependence on the presence
of at at least some observed value for each feature of interest. However, we consistently found
the TCGA dataset was missing observations of features of interest in any subject. As discussed
in Chapter 2, when the missing features are not of primary interest, namely, gene methylation
or copy number, or miRNA expression, we may simply omit them from the graph, and proceed
with our analysis of the signaling pathway, which is primarily defined over gene expression
vertices. But, this omission of missing features does not address the scenario in which gene
expression features are missing. In principle, one may omit vertices that are leaves or roots,
with in- and out-degree of one, respectively. But omitting the gene feature from the signaling
network may fundamentally alter the graph topology in a way that destroys the connectedness
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between other graph vertices. A latent variable model, on the other hand, might provide a
mechanism by which to save the analysis.
To implement such a model, in the first place, would require either an endogenous model of
the adjacency weights, as discussed above, or a “stand-in” default value for association weights.
Then, simulation-based methods could be employed to sample the unobserved values, in order
to permit pathway pass-through effects even in networks with missing gene vertices. Although
it is unlikely that the unobserved gene could be accurately or precisely analyzed inferentially,
this would at least enable pathway analysis in situations that are currently impossible because
of missing features, despite most features being observed.
Finally, much work remains for subpathway identification. The assumption that the single
most significant gene in a pathway will also be in the most significant subpath is a strong one,
and it is entirely possible that no individual gene as seed will yield the maximally-significant
subpathway. Nonetheless, an initial remedy would be to use each gene in the pathway as a
seed, to identify its corresponding greedy pathway. This is possible in principle through our
interactive data analysis, which lets the user select a gene to use as a seed for the greedy
subpathway algorithm. To procedurally identify a single significant subpathway from many
generated from multiple seeds, we require on the one hand an integration or consensus method
to combine subpathways from different seeds, and on the other hand, a compatibility score to
identify when there is no significant subpathway. This would be a function of the compatibility
or overlap of subpathways generated from different seeds.
Computational cost of subpathway identification remains high, but it is not apparent where
savings might be found: the initial estimation of the pathway model is a fixed cost, and the
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greedy algorithm must proceed iteratively, expanding the subpathway by a single vertex at
each step. However, the computational cost for an individual pathway is minimal, so some
computational time can be reduced by parallelization when considering a large number of
pathways. At this point, we have only implemented the subpathway algorithm for NetGSA on
expression only, and EMC-NetGSA. A natural next step is to apply the same method to the
miRNA-EMC-NetGSA analysis, to identify subpathways with the miRNA-gene target effects
accounted for.
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